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ABSTRACT OF THE DISSERTATION
Clinical Application of Electrocardiographic Imaging
In Patients with Ischemic Cardiomyopathy,
Early Repolarization Syndrome and Brugada Syndrome

by
Junjie Zhang
Doctor of Philosophy in Biomedical Engineering
Washington University in St. Louis, 2015
Professor Yoram Rudy, Chair

Electrocardiographic Imaging (ECGI) is a noninvasive modality for human application in
both research and clinical settings. It is an important tool for investigation of abnormal
electrophysiological (EP) substrates and arrhythmias in patients. Multi-channel body surface
potential recordings and the patient-specific heart-torso geometry from ECG gated computed
tomography are processed by ECGI algorithms to reconstruct epicardial potentials, electrograms
and patterns of activation and repolarization. ECGI is able to continuously generate high-resolution,
panoramic EP maps of the entire heart on a beat-by-beat basis, which cannot be achieved with
invasive catheter mapping.
ECGI was applied in ischemic cardiomyopathy patients to characterize the abnormal EP
substrate associated with myocardial infarction. In patients who developed ventricular tachycardia
during the study, the arrhythmia activation pattern and site of origin were correlated with the EP

xi

substrate to identify components of the reentry circuit. The study subjects included patients with
and without a history of clinical ventricular arrhythmias. The properties of scar EP substrate were
compared between the two groups to determine whether substantial differences exist. This
differentiating capability of ECGI was examined as a potential tool for arrhythmic risk stratification
in this population.
In a separate clinical study, ECGI was applied in a group of patients with early
repolarization syndrome, which has been recently shown to be associated with an increased risk of
ventricular fibrillation. The ventricular activation and repolarization patterns during sinus rhythm
were characterized and compared with data from normal controls. This study aimed to provide
insights into the mechanisms of the early repolarization ECG pattern and the related
arrhythmogenesis.
ECGI was also applied in patients with Brugada syndrome to image the EP substrate and to
study the underlying mechanisms of the Brugada ECG pattern and abnormal epicardial
electrograms. Heart rate change protocol in selected patients helped unmask the coexistence of
abnormal conduction and abnormal repolarization in the EP substrate. Brugada syndrome patients
were also compared with patients with right bundle branch block (generally considered benign) to
determine whether the substrate was specific to Brugada syndrome, and whether ECGI can
differentiate between these two pathologies with similar ECG patterns.
The above studies demonstrated the feasibility and clinical importance of ECGI for
noninvasive diagnosis, pre-procedural guidance and arrhythmic risk stratification in human subjects.

xii

Chapter 1:

Introduction

Cardiac electrical activity is a complex process. Each cardiac cycle starts with fast
depolarization of the myocytes in the sinoatrial node. The electrical impulse spreads to the
myocardium via the cardiac conduction system. The ordered and rhythmic excitation of the
myocardium during each cardiac cycle ensures efficient contraction of the heart. Immediately after
the depolarization phase, the myocardial cells start to repolarize, a relatively slow process that
brings the membrane potential back to the resting voltage.
Pathological changes can affect the membrane excitability (by down-regulating the sodium
current), change the tissue structure (by causing fibrosis or by affecting gap-junction expression
and distribution), and modify myocardial refractoriness (by disturbing current balance during the
repolarization phase). These electrophysiological (EP) and structural changes can lead to slow,
discontinuous propagation of the action potential through the cardiac tissue and steep gradients of
myocardial repolarization, creating abnormal EP substrates that support initiation and maintenance
of fatal reentrant arrhythmias.
The 12-lead ECG is the only routine noninvasive tool for diagnosis and detection of cardiac
rhythm disorders. Since its first introduction in 1902 by Einthoven, the 12-lead ECG has become
a major clinical tool in assessing the function of the heart. However, in clinical practice, it is
difficult to relate the ECG signals directly to the actual electrical activation and recovery processes
in the heart. Each ECG electrode on the body surface records a signal that reflects integrated
electrical activity over the entire heart. The ECG recordings are also smoothed by the torso-volume
conductor. Therefore, the conventional 12-lead ECG lacks spatial resolution, sensitivity and
specificity.
1

Electrocardiographic Imaging (ECGI)1-20 is a noninvasive modality for human application
in both research and clinical settings. It has become an important tool for investigation of
arrhythmogenic substrates and arrhythmias in patients. ECGI overcomes the limitations of
conventional ECG by providing physiologically relevant information about cardiac electrical
activity and reconstructing the actual spatial properties on the surface of the heart.

1.1

The ECGI Methodology
The electric potential field ϕ, generated by excitation of the heart in the surrounding torso

volume between the epicardium and the body surface, obeys Laplace’s equation. Torso surface
potentials (ϕT) can be measured by electrodes placed on the body surface. ϕE, epicardial potentials,
is the unknown variable to be solved for. Application of Green’s second theorem and discretization
of the epicardial and torso surfaces into triangular elements yields the following matrix equation
relating ϕT to ϕE:21
A ϕE = ϕT

1.1

The transfer matrix A contains the heart-torso geometric information. The objective of ECGI is to
compute ϕE from a known ϕT, a procedure that constitutes the inverse problem of
electrocardiography. The inverse problem is ill-posed22-23 in the sense that direct inversion of
transfer matrix A leads to unstable solution. Two different computational schemes have been
applied to suppress errors in the inverse solution: Tikhonov regularization22-23 (a method that
imposes constraints on ϕE) and the generalized minimal residual (GMRes) iterative technique.9, 24
The ECGI procedure is shown in Figure1-1. To obtain ϕT, multi-electrode strips are applied
to the patient’s torso; up to 256 electrocardiograms are recorded simultaneously. To obtain transfer
matrix A, the patient-specific heart-torso geometry is acquired via ECG-gated computed
2

tomography. These two sets of data are processed by ECGI algorithms to reconstruct epicardial
potentials, unipolar electrograms (EGMs), and high-resolution maps of activation and
repolarization. The reconstruction is performed during a single beat and does not require
accumulating data from multiple identical beats. This property makes it possible to image nonsustained and polymorphic arrhythmias, and arrhythmias that are not hemodynamically tolerated.

Figure 1-1: ECGI Procedure
The noninvasive ECGI procedure. Body surface potential recordings (256 electrodes) and gated,
non-contrast thoracic computed tomography scan are processed mathematically to obtain
epicardial potentials, 1500 unipolar electrograms, and maps of epicardial activation and
repolarization.

1.2

Validation of ECGI in Animal Models and Human Studies
Validation experiments in animal models showed that ECGI can reconstruct EGMs with

good accuracy, including in infarcted hearts, where EGMs inside the scar region display low
potentials and fractionation.1-2, 4-5 ECGI was also shown to accurately reconstruct repolarization
properties and to localize areas of increased dispersion of repolarization.6 Later, ECGI was
validated in human subjects with direct intra-operative mapping during open-heart surgery.11 It
3

was shown that ECGI-reconstructed isochrones captured sites of earliest activation, areas of slow
conduction, and the general excitation pattern. In addition, ECGI demonstrated a high spatial
resolution of 6 mm for determining initiation sites (induced by pacing).
Recently, ECGI was applied to study patients with a history of myocardial infarction.16 The
location, size and shape of the electrical scar imaged by ECGI co-localized to the anatomic scar
imaged by late gadolinium enhancement MRI or single-photon emission computed tomography
with high accuracy. In a separate study, diverse ventricular arrhythmia activation patterns,
mechanisms, and sites of origin in human subjects have been described in detail using ECGI.17
These studies in humans showed great promise and paved the way for further clinical application
of this novel technique as presented in this dissertation.

1.3

Dissertation Organization
Chapter 2: Application of ECGI in ischemic cardiomyopathy (ICM) patients. Scar-

related ventricular arrhythmias are the most common cause of rhythm disorders and sudden cardiac
death (SCD) in patients who suffered myocardial infarction. Catheter ablation utilizing activation
mapping and substrate mapping has evolved to treat scar-related ventricular arrhythmias. However,
this invasive mapping procedure is difficult, time consuming and involves substantial risk. Given
the increased risk of SCD associated with scar-related arrhythmias, the implantable cardioverterdefibrillator (ICD) has been prescribed for ICM patients. The clinical criterion for ICD
implantation in these patients is based almost exclusively on reduced left ventricular ejection
fraction. However, only a small percentage of ICM patients who undergo device implantation
receive appropriate shocks, making the reactive therapy with ICD unsatisfactory. In this study,
noninvasive ECGI is used to map the EP substrate and VT circuits with high resolution and to
stratify arrhythmic risk in ICM patients.
4

Chapter 3: Application of ECGI in early repolarization syndrome (ERS) patients:
The ER pattern is a common ECG finding. Recent studies established a definitive clinical
association between ER and fatal ventricular arrhythmias. Although ER has been extensively
studied at the molecular and cellular levels, information on the EP substrate and arrhythmic
behaviors of the intact human heart in vivo, where arrhythmias occur, is missing. With limited
sensitivity, specificity and spatial resolution, the ECG characteristics are inadequate measures of
the underlying activation and repolarization properties. The aim of this study is to characterize the
epicardial EP substrate in ERS patients and to investigate how ERS predisposes patients to an
increased risk of ventricular arrhythmias.
Chapter 4: Application of ECGI in Brugada syndrome (BrS) patients: BrS is a highly
arrhythmogenic cardiac disorder, associated with an increased incidence of SCD. It is estimated
that BrS causes approximately 20% of SCD in cardiac patients with structurally normal heart.
Understanding its pathophysiological mechanisms is essential for improving risk stratification,
diagnosis and treatment to prevent SCD. While much is known at the molecular and cellular scales,
understanding the cause of the BrS ECG pattern and associated arrhythmias requires detailed
characterization of the EP substrate in the intact hearts of BrS patients. The goal of this study is to
characterize the EP substrate in BrS patients using high-resolution panoramic EP maps generated
by ECGI, in an effort to provide insight into the mechanistic origin of the BrS phenotype.
Chapter 5 finishes the dissertation with concluding remarks and a discussion of future
work that can be done to improve the work presented here.

5

Chapter 2:

Noninvasive High-Resolution Cardiac Mapping in

Ischemic Cardiomyopathy Patients: the Electrophysiological
Substrate in Relation to Ventricular Arrhythmias and Arrhythmic
Risk
2.1

Abstract
Ventricular tachycardia (VT) occurs frequently in the setting of myocardial infarction.

Additional methods are needed for mapping the electrophysiological (EP) substrate and VT
circuits with high resolution and for stratifying VT risk in ischemic cardiomyopathy (ICM)
patients.
Noninvasive epicardial mapping with Electrocardiographic Imaging (ECGI) was
performed in 32 patients with ICM (17 with clinical VT, 15 without VT). Abnormal EP scar
substrate was determined based on low electrogram voltage (as percentage of maximal peak-topeak voltage over the entire ventricular epicardium; total scar-TS <30%; dense scar-DS <15%).
Scar burden was defined as the ratio of the scar size to the total epicardial surface area. Scar
heterogeneity was characterized by presence of electrogram fractionation. Late potentials (LPs)
were deflections that occurred after completion of global epicardial activation. Patients with VT
had higher scar burden (TS: 51.0±9.3% vs. 36.5±5.4%, p<0.05; DS: 29.5±7.3% vs. 16.8±6.8%,
p<0.05) with lower unipolar electrogram voltage (TS: 1.34±0.34 vs. 1.91±0.39 mV, p<0.05; DS:
0.91±0.29 vs. 1.22±0.33 mV, p<0.05), greater prevalence of fractionated electrograms (TS:
44.1±10.6% vs. 26.8±6.3%, p<0.05; DS: 50.8±10.8% vs. 30.9±7.0%, p<0.05) and LPs (TS:
26.8±10.7% vs. 15.8±5.3, p<0.05). VTs were mapped in 8 patients; the reentry circuits were
closely related to the EP substrate.
6

ECGI identifies scar EP properties that underlie abnormal conduction and VT in ICM
patients. It also correlates VT activation patterns with the scar EP substrate. ECGI can potentially
be used for VT risk stratification in ICM patients.

2.2

Introduction
Scar-related ventricular arrhythmias are the most common cause of rhythm disorders and

sudden cardiac death (SCD) in patients who suffered myocardial infarction (MI). Healed infarcts
can produce abnormal electrophysiological (EP) substrates that support arrhythmogenicity. With
inexcitable scar tissue separating islands of surviving myocardial fibers, the EP substrate tends to
have an inhomogeneous structure.25-26 This heterogeneity is associated with slow discontinuous
conduction, direction-dependent conduction blocks and the presence of conducting channels
within the scar, which can ultimately facilitate the formation and maintenance of reentrant
arrhythmias.27-29
Catheter ablation utilizing activation mapping (complemented by entrainment and pacemapping) has evolved to treat scar-related VT with up to 75% success rate after successful
mapping procedures.30 However, non-sustained, non-inducible, or hemodynamically unstable VTs
cannot be mapped by this technique. Alternatively, substrate mapping can be performed during
sinus rhythm (SR), which does not require prolonged periods of ventricular tachycardia (VT). This
procedure identifies the EP substrate associated with myocardial scars. In the scar, regions with
low-voltage, fractionated electrograms (EGMs), slow conduction and late potentials (LPs) are
considered critical components for reentrant arrhythmias.31-33 This information is used to guide
substrate-based ablation for interruption of the reentry circuit and elimination of VT. However, the
invasive mapping procedure is difficult, time consuming and involves substantial risk. Moreover,
it only maps the substrate, instead of the actual reentry circuit. Due to the point-by-point sampling
7

nature of catheter mapping, some critical sites might be missed. Thus, a need exists to develop
alternative techniques to map both the VT circuits and the EP substrate with high resolution.
Given the increased risk of SCD associated with scar-related arrhythmias, the implantable
cardioverter-defibrillator (ICD) has been prescribed for ischemic cardiomyopathy (ICM) patients.
The clinical criterion for ICD implantation in these patients is based almost exclusively on reduced
left ventricular ejection fraction (LVEF). However, approximately 20% of ICM patients who
undergo device implantation receive appropriate shocks, making the reactive therapy with ICD
unsatisfactory.34 Clearly, new methods and better criteria are needed for arrhythmia risk
stratification of ICM patients.
Recent developments in noninvasive Electrocardiographic Imaging (ECGI; also called
ECG mapping, ECM) have demonstrated its clinical usefulness in studying the EP properties and
mechanisms of a variety of pathologies in the intact human heart. ECGI provides panoramic, highresolution EP data with up to 1,500 unipolar epicardial EGMs that cover both ventricles, from
which epicardial maps of activation and repolarization can be generated.1, 5, 10, 13, 16-17, 20 Important
to this study, ECGI can identify and characterize the abnormal EP substrate (low-voltage,
fractionated EGMs and the presence of LPs) on the epicardial aspect of myocardial scars.5, 16 The
location, size and shape of the electrical scar imaged by ECGI co-localized to the anatomic scar
imaged by late gadolinium enhancement MRI (LGE-MRI) or single-photon emission computed
tomography (SPECT) with high accuracy.16 In addition, ECGI mapping is accomplished during a
single beat, making it capable of mapping premature ventricular contractions (PVCs), and
polymorphic and unstable VTs. Diverse VT activation patterns, mechanisms, and sites of origin in
human subjects have been described in detail using ECGI.17 In the current study, based on highresolution ECGI data recorded during sinus rhythm (SR), we characterize the EP substrate in ICM
8

patients. We correlate the activation pattern and site of origin during VT (if present) with the EP
substrate map to identify components of the reentry circuit. We also compare the EP substrate
between ICM patients with and without VT, to determine whether substantial differences in EP
properties exist. This differentiating capability of ECGI is examined as a potential tool for
arrhythmic risk stratification in ICM patients.

2.3
2.3.1

Methods
Patient Population
The control group consisted of ICM patients with (1) history of MI (at least 6 months

elapsed since the most recent MI), (2) systolic dysfunction with left ventricular ejection fraction
(LVEF) ≤35%, (3) an implantable cardioverter-defibrillator (ICD) inserted based on primary
prevention criteria, and (4) no history of clinical ventricular arrhythmias, syncope or cardiac arrest
for at least 48 months since ICD insertion. The case group shared criteria (1) and (2) with the
control group. In addition, the case group patients experienced at least one episode of clinical VT
post-MI. These patients may have an ICD inserted for the primary prevention of SCD, but it was
not required. Patients with the following conditions were excluded:35 (1) Surgical or percutaneous
revascularization within the last 6 months; (2) Decompensated cardiac failure within the last
month; (3) Uncontrolled hypertension; (4) Active cerebrovascular disease (or stroke within the last
6 months); (5) Electrolyte abnormalities. All protocols were approved by the Institutional Review
Boards at Washington University; written informed consent was obtained from all patients.
2.3.2

Noninvasive Mapping
ECGI methodology was described previously.1, 5, 10, 13, 16-17, 20 Multi-channel body surface

potential mapping with 256 electrodes was performed during SR in all patients and during
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arrhythmic period in patients who developed VT or PVCs at the time of the study. Patient-specific
heart-torso geometry was obtained via non-contrast ECG-gated computed tomography. The hearttorso geometrical information was combined with the body surface potential data to noninvasively
reconstruct epicardial potentials, unipolar electrograms, and high-resolution maps of activation,
repolarization and EP substrate associated with myocardial scar. The method was validated
extensively for reconstruction of EGMs,1, 5 activation10, 13 and repolarization.13
Clinical noninvasive cardiac imaging, including LGE-MRI (2 patients) and myocardial
perfusion imaging with SPECT (30 patients), was available for comparing anatomical scar to
ECGI-reconstructed electrical scar.
2.3.3

Data Analysis
Characteristics of the abnormal EP substrate associated with MI were analyzed by using

data recorded during SR. EGM magnitude was measured peak-to-peak during the EGM QRS.
Because the absolute EGM magnitude was influenced by patient-specific factors such as body
habitus and heart-torso geometry, the EP substrate was defined based on EGM magnitude as a
percentage of the maximal EGM magnitude of all EGMs reconstructed over the entire epicardium
for each patient (total scar: <30%; dense scar: <15%; peripheral scar: between 15% and 30%). Scar
burden was defined based on the size of total scar, dense scar and peripheral scar as a percentage
of total epicardial surface area.
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Figure 2-1: Far-field Potential Identification.
Panel A shows a unipolar EGM reconstructed in the scar region. It is of low voltage and includes
3 deflections (squares). The timing of the second deflection matches the activation time of a
remote EGM (Panel B, about 2 cm away). Therefore, it was considered far-field potential and
was excluded from fractionation analysis.

The spatial resolution of ECGI was about 2 to 6 mm.12 The degree of scar heterogeneity
was quantified by EGM fractionation. Fractionation was expressed as the number of intrinsic,
sharp deflections (dV/dt <-0.05 V/s) per EGM. Each EGM reflected the electrical activity in
cardiac tissue beneath and adjacent to the EGM location. For fractionated EGMs, deflections due
to far-field activities were identified if the timing of the deflections matched the timing of
deflection(s) in neighboring EGMs, remote EGMs, or both (Figure 2-1). Far-field deflections were
marked and excluded for fractionation analysis. The remaining deflections were considered local
activations. The sharpest local activation with the maximal negative slope was used to create the
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global activation isochrone map. LPs were defined as local activations with magnitude above the
ambient electrical noise level that occurred after the completion of global epicardial activation.
The presence of conducting channels within abnormal EP substrate was inferred if a
continuous region of higher amplitude signals within the substrate could be observed after
adjusting the threshold and color scale of the EGM voltage map.
Activation time (AT) was determined by the maximal negative slope of the EGM during
QRS inscription. All ATs were referenced to the beginning of QRS in ECG lead II. Epicardial
activation isochrone maps were created from ATs. Lines of conduction block were inferred if
adjacent ATs differed by more than 50 ms. Slow conduction was represented by crowded
isochrones.
Local recovery time (RT), which reflects the sum of local AT and local action potential
duration (APD), was determined from the maximal positive slope of the EGM T-wave. For a given
activation sequence, RT determines spatial voltage gradients during repolarization. Activationrecovery interval (ARI) was defined as the difference between RT and AT. ARI is independent of
AT and a surrogate for local APD.
ECGI analyzed ventricular arrhythmias from a single beat and did not require accumulating
data from multiple identical beats. Each arrhythmia was characterized and analyzed based on the
global activation isochrones, properties of local EGMs, and patterns of wavefront propagation and
its relationship to the EP substrate.
2.3.4

Statistical analysis
All continuous data are presented as mean±SD. Categorical data were analyzed by the chi-

square test (or Fisher’s exact test). Continuous variables were analyzed by unpaired t-test. The
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Satterthwaite modified t-test was used for variables with unequal variances. The Mann-Whitney
U test was used for variables with non-normal distribution. All tests with P<0.05 were considered
statistically significant. Statistical analysis was performed by using SPSS v19.

Control Group:
Non-VT Patients
15

P
Value

N

Case Group:
VT Patients
17

Age, years

70±10

68±15

NS

Male

16(94%)

13(87%)

NS

Left ventricular ejection
fraction , %

24±6

25±5

NS

QRS duration, ms

135±22

142±25

NS

Mean time since MI,
months

90±31

96±21

NS

Anterior

6(35%)

3(20%)

NS

Inferior

9(53%)

11(73%)

NS

Apical

10(59%)

8(53%)

NS

Beta-blocker

17(100%)

15(100%)

NS

ACE/ARB

17(100%)

15(100%)

NS

Amiodarone

14

0

<0.001

Other antiarrhythmic drugs

6

0

<0.001

Characteristics

Infarct
Location

Table 2-1: Cumulative Patient Characteristics
Data are presented as mean±SD or number (percentage). ACE= angiotensin-converting enzyme
inhibitors; ARB= angiotensin receptor blockers; MI= myocardial infarction; NS= not significant;
VT= ventricular tachycardia.

2.4

Results
Between March 2010 and March 2014, 32 ICM patients were enrolled in this study,

including 15 patients with no history of clinical ventricular arrhythmias (control group) and 17
patients with spontaneous VT (case group). Patient characteristics are provided in Table 2-1.
Overall, the two groups had similar characteristics in terms of age, gender, LVEF, QRS duration,
13

time since MI and infarct distribution. All patients were treated by beta-blocker and angiotensinconverting enzyme inhibitors/ angiotensin receptor blockers. All case group patients were treated
by antiarrhythmic drugs, whereas none of the control patients were on antiarrhythmic drugs.

Figure 2-2: Representative Electrograms (EGMs)
Panel A: EGM from scar region. Panel B: EGM from non-scar region. Each panel shows a
reconstructed unipolar EGM (top) and the corresponding time derivatives (dV/dt; bottom). The
time derivative approximates a bipolar EGM and emphasizes fractionation. Squares indicate
intrinsic sharp deflections (steep negative dV/dt), reflecting local activation. The dashed line
indicates the time when global epicardial activation has been completed. L= local activation, G=
global activation, LP= late potential. Note that the EGM from the scar region has a low voltage
and multiple deflections.

2.4.1

Characteristics of Abnormal EP Substrate
Figure 2-2A shows a reconstructed epicardial unipolar EGM (top) and its time derivatives

(dV/dt; bottom) from inside a scar. The time derivative approximates a bipolar EGM and helps to
emphasize fractionation. In this example, the EGM has low voltage and 3 deflections, reflecting 3
local activation events. The second deflection has the sharpest negative slope and was taken as the
AT for constructing the global isochrone map. The third deflection occurred after the completion
of global epicardial activation (the latest activation over both ventricles) and was considered a LP.
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A normal EGM at a site remote from the scar and its derivative are shown in Figure 2-2B for
reference.
Examples of abnormal EP substrate in a non-VT patient and a VT patient are shown in
Figure 2-3 and Figure 2-4, respectively. Data for all patients are shown in the supplemental
material (Section 2.7, Figure 2-7 to Figure 2-38). EP substrate for a non-VT patient is shown in
Figure 2-3. Patient #27 was a 69 year-old male with LVEF of 28%. After suffering MI in 2006, he
received a pacemaker/ICD device for primary prevention of SCD. He never had any arrhythmic
event since the ICD insertion. Based on SPECT images (Panel F), large irreversible perfusion
abnormality of marked severity involved the entire inferior, infero-lateral and infero-septal walls.
The voltage map identified the electrical scar on the inferior wall (Panel B, red). By adjusting the
threshold and color scale of the voltage map, the scar architecture could be observed and studied
with high-resolution. The dense scar (Panel C, orange) separated strands of tissue with preserved
voltage (Panel C, cyan). Fractionated EGMs (Panel D, yellow, red) and late potentials (Panel E,
red) were seen inside the electrical scar. Normal human epicardial activation during SR was
reported previously.13 In general, ventricular epicardial activation starts with right ventricular (RV)
breakthrough, then propagates smoothly and uniformly towards the basal lateral left ventricle
(LV). Activation isochrone map in this patient (Panel A) showed that the epicardial activation
pattern during SR was altered by the presence of the inferior scar. After the normal RV
breakthrough (asterisk), the activation wavefront could not proceed towards the inferior RV (lineof-block at the scar border, black arrows). This forced activation of the inferior wall in a left-toright pattern, leaving the inferior RV the latest region to activate. The scar burden in this patient
was: total scar =30%, dense scar =14%, peripheral scar =16% of total epicardial surface area.
Prevalence of fractionated EGM was 28% in the total scar, 32% in the dense scar and 25% in the
15

peripheral scar. Prevalence of LP was 10% in the total scar, 12% in the dense scar and 9% in the
peripheral scar.

Figure 2-3: The abnormal electrophysiological substrate in a non-VT patient (control)
with an inferior infarct.
Panel A: Activation isochrone map. Panel B Global voltage map; magnitude of unipolar
electrograms. Panel C: High-resolution scar voltage map with adjusted threshold and color scale.
Panel D: Electrogram fractionation; number of intrinsic deflections per electrogram. Panel E:
Late potentials; regions with late potentials shown in red. Panels A-E display the heart in anterior
view (left) and inferior view (right). Panel F: Single-photon emission computed tomography
(SPECT) anatomic scar in a standard “bullseye” configuration or apical view (left) and long-axis
view (right). In panel A, epicardial breakthrough is indicated by an asterisk, isochrones are
depicted with thin black lines, and black arrows point to conduction block at the border of the
inferior infarct. LA= left atrium; LV= left ventricle; RA= right atrium; RV= right ventricle.
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Figure 2-4: The abnormal electrophysiological substrate in a VT patient (case)
This patient had a large apical infarct, extending anteriorly and inferiorly. Same format as Figure
2-3. In panel A, black arrows point to conduction block along the septum.

Figure 2-4 shows the EP substrate in a VT patient. Patient #3 was a 72 year-old male with
LVEF of 27%. He had multiple episodes of MI in 1980, 1987 and 1990, complicated by VTs.
SPECT images (Panel F) suggested the presence of large, severe infarct involving the anterior,
inferior, septal, and lateral walls and centering on the apex. ECGI co-localized an extensive apical
scar that extended into the mid-myocardium (Panel B, red and orange). The only region with
normal-voltage EGMs was the ventricular base. High-resolution voltage map identified several
corridors with higher voltage (Panel C, light blue, green; near apex, inferior wall and lateral wall)
17

that penetrated the dense scar. Fractionated EGMs (Panel D, yellow, red) and late potentials (Panel
E, red) were seen inside the electrical scar. Activation isochrone map (Panel A) showed a delayed
activation of the LV as a result of the extensive infarct. Lines-of-block (black arrows) were seen
over the interventricular septum. Anterior and inferior LV base were the latest regions to activate,
about 80 ms later than in normal hearts.13 The scar burden in this patient was: total scar =67%,
dense scar =44%, peripheral scar =23% of total epicardial surface area. Prevalence of fractionated
EGM was 58% in the total scar, 59% in the dense scar and 56% in the peripheral scar. Prevalence
of late potentials was 39% in the total scar, 31% in the dense scar and 43% in the peripheral scar.

Figure 2-5: The electrophysiological substrate in relation to ventricular arrhythmias.
Panel A: Apical scar related ventricular tachycardia (VT) with a single reentrant loop. Panel B:
Anterior scar related VT with a double-loop pattern. Each panel shows the VT activation map
(top), possible conducting channels (dashed lines) that facilitated VT (bottom left), a fractionated
electrogram (EGM) with late potentials (LPs) during sinus rhythm (SR) (bottom right; yellow
arrows point to EGM location). The VT initiation sites are indicated by plus signs “+”. In top
panels, zigzag arrows indicate very slow conduction that crossed the scar border and reentered
the VT initiation site. In panel A, the white arrows indicate a clockwise apical loop. In panel B,
the white arrows indicate propagation of the inferior wavefront and the black arrows indicate
propagation of the superior wavefront. CL= cycle length. Activation movies for both VTs are
provided in the attached CD (Movie 2-1 and Movie 2-2, respectively).
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2.4.2

Relationship between Ventricular Arrhythmias and EP Substrate
Figure 2-5 presents two examples of scar-related reentrant VT. Panel A shows an apical

scar related VT with a simple activation pattern from patient #3 (substrate shown in Figure 2-4).
A short run of non-sustained VT with a cycle length (CL) of 410 ms was recorded and analyzed.
The earliest epicardial activation was in the anterior mid wall near the septum (plus sign), a
peripheral scar region based on the EGM voltage criterion. The activation wavefront exited the
anterior wall at the beginning of the VT beat, then activated sequentially in a clockwise pattern the
lateral LV, inferior wall and anterior RV (white arrows), and reentered to complete one VT cycle
(zigzag arrow). A movie of the activation sequence is provided in the attached CD (Movie 2-1).
Panel B presents an anterior scar related VT with a complex activation pattern from patient #8
(substrate shown in Figure 2-14, Page 37). The patient developed non-sustained VT (CL =397 ms)
during the ECGI procedure. The site of VT origin was located in the anterior mid wall near the
apex, inside a region of the scar with preserved voltage (plus sign). The activation wavefront exited
this region in two directions. The inferior wavefront propagated towards the apex (white arrows)
then towards the inferior wall before it entered the anterior mid-RV, forming a clockwise apical
loop. The superior wavefront propagated towards the base then bifurcated (black arrows). The left
branch of the superior wavefront activated the LV base, and merged with the inferior wavefront at
the inferior base. The right branch of the superior wavefront circumvented the dense scar, then
propagated slowly into the superior RV in a counterclockwise fashion. The anterior mid-RV was
the region where the right branch of the superior wavefront met the inferior wavefront, and was
the latest region to activate in the VT cycle. From here, the VT wavefront slowly propagated
through the anterior scar (zigzag arrow) and reentered the site of origin. A double-loop pattern
could be seen in the anterior view of the VT activation map. The lateral LV activated late, because
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the activation wavefront was blocked at the lateral dense scar. A movie of the activation sequence
is provided in the attached CD (Movie 2-2).
For both cases, possible conducting channels that could have facilitated the VT formation
and conduction were identified and labeled with dashed lines (Figure 2-5, bottom panels). EGMs
with low voltage, fractionation and late potentials were recorded during SR at and near the site of
VT origin (Figure 2-5, right of bottom panels),These EGMs reflected local diastolic activities at
the scar border (zigzag arrows), indicating slow, discontinuous and non-uniform conduction
through the scar.
Among 17 patients with a history of spontaneous VT, 8 developed ventricular arrhythmia
during the ECGI procedure, including non-sustained VT in 6 patients and frequent PVCs in 2
patients. The site of origin was localized to the dense scar in 2 patients, to the peripheral scar in 5
patients, and to the non-scar region in 1 patient. SR EGMs at or near the VT/PVC site of origin
showed fractionation and LPs in all 8 patients. Only one of these arrhythmias were originated from
regions with latest SR activation.
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Figure 2-6: Comparison of the electrophysiological substrate properties between VT
patients (case) and non-VT patients (control)
Panel A: Scar burden (scar size as percentage of total epicardial surface area). Panel B: Mean
unipolar voltage. Panel C: Percentage of fractionated electrograms (EGMs) within total scar,
dense scar and peripheral scar. Panel D: Prevalence of late potentials (LPs). Percentage of EGMs
with LPs within total scar, dense scar and peripheral scar. Panel E: Latest activation detected after
completion of global epicardial activation. Timing is referenced to the latest epicardial activation
time. Panel F: Number of conducting channels per patient. P<0.05 is marked with an asterisk.

2.4.3

Comparison of EP Substrate Properties between VT Patients and Non-VT patients
Figure 2-6 summarizes the differences in the EP substrate between patients with VT (case)

and patients without VT (control). When controlled for total epicardial surface area, VT patients
had higher proportion of total scar (51.0±9.3% vs. 36.5±5.4%, p<0.05) and dense scar (29.5±7.3%
vs. 16.8±6.8%, p<0.05) than non-VT patients (Panel A). There was no significant difference
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between the groups with respect to the proportion of peripheral scar (21.5±6.6% vs. 19.7±6.1%,
p=0.43). The mean unipolar voltage (Panel B) was significantly lower in VT patients than in nonVT patients within the total scar (1.34±0.34 vs. 1.91±0.39 mV, p<0.05), the dense scar (0.91±0.29
vs. 1.22±0.33 mV, p<0.05) and the peripheral scar (1.97±0.49 vs. 2.58±0.67, p<0.05). Fractionated
EGMs were observed in every patient. VT patients had higher percentage of fractionated EGMs
within the total scar (44.1±10.6% vs. 26.8±6.3%, p<0.05), the dense scar (50.8±10.8% vs.
30.9±7.0%, p<0.05) and the peripheral scar (35.0±13.7% vs. 23.5±9.0%, p<0.05), respectively
(Panel C). LPs were observed in every patient also. VT patients had higher percentage of EGMs
with LPs within the total scar (26.8±10.7% vs. 15.8±5.3, p<0.05) and the peripheral scar
(31.8±12.3% vs. 17.1±6.4%, p<0.05), respectively (Panel D). The 2 groups had similar prevalence
of LPs within the dense scar (20.4±11.3 % vs. 15.5±8.2%, p=0.17). If LP was present in an EGM,
the timing of each late component was measured in reference to the completion of epicardial
activation. The mean value of latest activation was slightly higher for the VT group (48.8±14.5 vs.
40.1±12.5 ms, p=0.08), but the difference did not reach statistical significance (Panel E). Voltage
channels were found in all VT patients and 10 non-VT patients. VT patients had more channels
per patient than non-VT patients (3.1±1.2 vs. 1.7±1.2, p<0.05).
Global repolarization properties were measured and compared between the groups,
including mean RT, mean ARI, RT dispersions and ARI dispersions. No significant differences
were found in these parameters (Table 2-2).
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ECGI-derived Parameters
Total Scar
Dense Scar
Scar Size (%)
Peripheral
Scar
Total Scar
Mean Unipolar
Dense Scar
Voltage (mV)
Peripheral
Scar
Total Scar
Prevalence of
Fractionated
Dense Scar
EGMs within
Peripheral
(%)
Scar
Total Scar
Dense Scar
Prevalence of
Peripheral
LP within (%)
Scar
Number of conducting
channels
Latest LP (ms)
Apex-to-base ARI Dispersion
(ms)
Apex-to-base RT Dispersion
(ms)
RV-to-LV ARI Dispersion (ms)
RV-to-LV RT Dispersion (ms)
Mean ARI (ms)
Mean RT (ms)

Case Group:
VT Patients
51.0±9.3
29.5±7.3

Control Group:
Non-VT Patients
36.5±5.4
16.8±6.8

21.5±6.6

19.7±6.1

0.43

1.34±0.34
0.91±0.29

1.91±0.39
1.22±0.33

<0.05
<0.05

1.97±0.49

2.58±0.67

<0.05

44.1±10.6
50.8±10.8

26.8±6.3
30.9±7.0

<0.05
<0.05

35.0±13.7

23.5±9.0

<0.05

26.8±10.7
20.4±11.3

15.8±5.3
15.5±8.2

<0.05
0.17

31.8±12.3

17.1±6.4

<0.05

3.1±1.3

1.7±1.2

<0.05

48.8±14.5

40.1±12.5

0.08

43.7±9.8

49.3±10.3

0.13

55.3±11.8

60.3±10.2

0.22

45.1±8.3
59.3±9.5
260.7±18.4
336.6±25.3

48.5±7.8
62.2±10.9
271.2±15.0
349.5±22.1

0.23
0.43
0.09
0.14

P Value
<0.05
<0.05

Table 2-2: Comparison between VT Patients and Non-VT Patients
Data are presented as mean±SD.

2.5
2.5.1

Discussion
Key Findings
Key findings of this study include: (1) With noninvasive ECGI, the epicardial EP substrate

associated with MI was characterized by low-voltage and fractionated EGMs, the presence of LPs,
and altered SR activation pattern; (2) By correlating substrate maps with VT activation maps,
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critical substrate that supported the VT could be identified; (3) Repolarization abnormalities (such
as steep dispersion of repolarization) were not present in the substrate, indicating that the
mechanistic basis for conduction block and VT was structure-based abnormal propagation through
the scar substrate; (4) Significant differences existed in the EP substrate between VT patients and
non-VT patients: VT patients had greater epicardial scar burden, lower voltage in the scar, a higher
prevalence of fractionated EGM and LPs, and more conducting channels. These observations
explain to a certain extent the role of EP substrate in ventricular arrhythmia and the difference in
VT incidence between the groups. Given these findings, the study constitutes a first step towards
noninvasive arrhythmia risk stratification in ICM patients and pre-procedural guidance for scarrelated VT ablation.
2.5.2

The EP Scar Substrate
Following an ischemic event, a complex and progressive remodeling process occurs, which

changes the EP properties of the heart.25 In heterogeneous post-MI scars, strands of viable,
excitable myocardial fibers are separated by necrotic myocardium. This creates sites of
mismatched electrical properties with abrupt increases of electrical load that reduce the safety
factor for conduction and increase spatial dispersion of excitability.27 These changes can result in
reduced conduction velocity, discontinuous propagation through the infarct substrate, and regions
of conduction block - EP properties that promote reentrant arrhythmias. The scar-related abnormal
EP properties are reflected in low-voltage and fractionated EGMs, as was shown in experimental,
theoretical and clinical studies.29, 36-38
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2.5.3

Substrate Mapping and Ablation
Clinically, ICM patients are studied with invasive catheter mapping. If hemodynamically

stable VT can be mapped, critical pathways for reentry are identified and ablated. However,
extended period of VT cannot be tolerated by the majority of patients. Alternatively, substrate
mapping is performed during SR to identify regions with low-voltage, fractionated and prolonged
EGMs with LPs, as surrogate targets for ablation.
Recent substrate-based mapping and ablation studies suggested that complete LP abolition
is an effective strategy that yields good procedural outcomes.39-42 LPs identify excitable tissue that
supports very slow, discontinuous conduction and possibly regions of block. Beyond ablation of
the critical isthmus for VT, this approach requires ablation of all substrates that exhibit LPs to
achieve scar homogenization. A difficulty with LP mapping is that far-field potentials due to
depolarization of myocardial tissue remote from the recording electrode could be the source of
some LPs. In fact, ablating regions with LPs that reflect far-field activity may contribute to failure
of some substrate guided ablation procedures.39, 41 A recent study combined EGM analysis with
pace-capture to identify far-field potentials and refine identification of targets for substrate-based
ablation.43 In the present study, ECGI was used to identify directly far-field potentials in scar
EGMs and eliminate them from considerations of EGM fractionation.
2.5.4

ECGI-recorded Scar EGMs and Far-field Deflections
Previous validation studies demonstrated ECGI’s ability to reconstruct characteristics of

EGMs associated with post-MI scar in canine experiments.5 In a recent study, ECGI was
performed in 24 post-MI patients.16 Globally, the abnormal EP substrate on the epicardial aspect
of the scar was identified. It was characterized by low potentials, and presence of low-voltage
fractionated EGMs and LPs. The epicardial electrical scar imaged by ECGI co-localized to LGE25

MRI or SPECT with high accuracy (sensitivity 89%, specificity 85%). The current study dissected
the scar EP substrate with higher resolution and correlated it with the VT pattern. Because ECGI
provides panoramic maps of activation times, it can identify far-field potentials in local scar EGMs
by matching activation times in neighboring EGMs, remote EGMs, or both. This capability for
direct detection and exclusion of far-field deflections improved the accuracy of EGM fractionation
analysis. It enabled us to obtain high-resolution maps of voltage, EGM fractionation and LPs
within the scar, providing detailed spatial EP maps of the scar substrate. By correlating the VT
activation maps with the high-resolution ECGI images of the EP substrate obtained during SR,
critical components of the VT circuit could be identified and localized in the scar. These included
initiation sites, exit sites, and possible conducting channels.
2.5.5

Scar-related Arrhythmias
Arrhythmic events in 8 patients were imaged and analyzed. The ECGI-imaged reentry

circuits were closely related to the EP substrate with EGM fractionation and LPs. The data were
consistent with the findings from clinical studies,31 in which the isthmus for reentry circuit was
confined to a region of viable myocardium surrounded by the scar tissue. In 7 of 8 cases, the site
of origin was located near regions with LPs and low-voltage fractionated EGMs within the scar.
In one patient, the PVCs were found to originate from a location with a normal EGM magnitude,
but with fractionation and LP deflections. It is possible that this patient had a mild endocardial scar
near the PVC site of origin (not detectable by SPECT) and that the ECGI reconstructed epicardial
unipolar EGMs picked up diastolic activities from intramural locations. Since the epicardium
remained largely viable, the epicardial EGMs yielded normal magnitude but fractionation and LPs.
It is noteworthy that the majority of sites critical to reentry exhibited conduction slowing during
SR based on the activation isochrone map, but only one of them was found in a region with latest
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SR activation. The observation is consistent with invasive EP studies that suggested that regions
with conduction delay during SR may be critical for VT maintenance, and that zones with the most
delayed activation during SR may represent bystander sites irrelevant to the VT circuit. 44
Additionally, part of the inexcitable dense scar possibly served as an inert obstacle determinant of
the reentry circuit. As shown in Figure 2-5, the wavefront propagated around the dense scar with
high curvature after exiting from the site of origin.
2.5.6

Risk Stratification for VT
Earlier studies45-46 examining the EP substrate associated with MI provided initial insights

into the differences between VT and non-VT patients. However, they did not provide detailed EP
information due to limited endocardial sampling points. In a recent study, high-density endocardial
mapping collected detailed data from the dense scar region, and was used to compare ICM patients
with and without previous clinical ventricular arrhythmias.35 VT patients were found to have
markedly larger low-voltage zones, higher density of fractionated EGM, and more conducing
channels, which were the key markers of the VT substrate. In the current study, using noninvasive
ECGI, we compared the epicardial EP substrate between 17 ICM patients presenting with clinical
VT and 15 ICM patients who had an ICD inserted for primary prevention of SCD and had been
free from clinical episodes of VT for at least 48 months since ICD insertion. Despite the similar
patient characteristics of the 2 groups, the ECGI mapping data revealed that the VT patients had a
larger extent of total scar and dense scar EP substrate and lower voltage in the scar area.
Furthermore, the prevalence of EGMs with fractionation and LPs was greater in the VT patients.
The results add support to previous findings correlating substrate to VT incidence, and emphasize
the fact that the EP substrate for VT may or may not be present in patients with similar LV function.
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Not only the extent of the scar, but also its structural components that underlie spatial properties
of the EP substrate are important determinants of VT incidence.
2.5.7

Limitations
ECGI reconstructs potential maps and unipolar EGMs on the epicardial surface. These

provide information not only on the epicardial substrate; they reflect properties in the myocardial
depth as well.2 A previous study demonstrated high correlation between ECGI and imaging with
MRI and SPECT of transmural scars.16 However, activation isochrone mapping with ECGI is
limited to the epicardium. Scar-related reentry circuit may involve the endocardium, midmyocardium and epicardium. The earliest epicardial activation of VT may not accurately identify
the location of an endocardial circuit. Importantly, accumulating evidence demonstrates major
involvement of the epicardium in VT. A recent study predicted scar transmurality and the presence
of LPs in the epicardium based on the extension and density of the endocardial scar, indicating
possible requirement of an epicardial ablation procedure.40 The presence of an epicardial substrate
may be the reason for failure of a subset of endocardial procedures. A combined endocardialepicardial ablation strategy is associated with fewer readmissions for VT and repeat ablations
compared to only-endocardial ablation.47
The conducting channel in the scar was defined based on preserved EGM voltage during
SR. This study showed relationship between the conduction channels and the VT entry and exit
sites. However, slow conduction through the channel during VT cannot be directly mapped by
ECGI due to limited spatial resolution.
The extent of the ECGI-derived EP scar was determined by the threshold for EGM
magnitude. We adapted the threshold from a previous study, which correlated the EP scar to the
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anatomical scar with good levels of specificity and sensitivity.16 ECGI is also limited in its ability
to image small amplitude deflections during the repolarization period (T wave). Therefore, the
maps of LP distribution may not include all the LPs.
The generalizability of this study is limited by the relatively small number (32) of patients.
Future large-scale ECGI studies should be conducted to establish the potential of the approach for
noninvasive arrhythmic risk stratification in ICM patients prior to ICD implantation.

2.6

Conclusions
EP mapping with ECGI can overcome certain limitations of catheter mapping. It can

provide high-resolution maps of post-MI EP substrate together with panoramic maps of activation
during SR and VT. Being noninvasive, it reduces the procedural risk and can be repeated in followup studies during the remodeling process. Due to its single-beat mapping capability, it can map
polymorphic and unstable VT. It complements endocardial substrate mapping by providing highresolution images of the epicardial EP substrate. To our knowledge, this is the first noninvasive
EP mapping study in ICM patients that identifies key epicardial EP properties that may account
for the difference in VT incidence between VT and non-VT patients. It also correlates scar-related
arrhythmia patterns with high-resolution maps of spatial characteristics of the scar EP substrate
obtained during SR. With larger-scale studies, ECGI has the potential to become a clinical tool for
identification of ICM patients at high risk of arrhythmias for ICD indication and for pre-procedural
guidance of substrate-base ablation.

2.7
2.7.1

Supplemental Material
Maps of EP Substrate and Activation Sequence for VT Patients
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Figure 2-7: Patient #1: VT patient; inferior myocardial infarction
(A) Activation isochrone map. (B) Global voltage map; magnitude of unipolar electrograms. (C)
High-resolution scar voltage map with adjusted threshold and color scale. (D) Electrogram
fractionation; number of intrinsic deflections per electrogram. (E) Late potentials; regions with late
potentials shown in red. (F) Single-photon emission computed tomography (SPECT) anatomic scar
in apical view (left) and long-axis view (right); (G) VT activation map. Panels A-E and G display
the heart in anterior view (left) and inferior view (right). In panel A, epicardial breakthrough is
indicated by an asterisk “*”, isochrones are depicted with thin black lines, and black arrows point
to conduction block. In panel G, the VT site of origin is indicated by a plus sign “+”, curved arrows
indicate propagation of the VT wavefront.
The VT site of origin was localized to the peripheral scar near the inferior base.
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Figure 2-8: Patient #2: VT patient; inferior myocardial infarction
(A) Activation isochrone map. (B) Global voltage map; magnitude of unipolar electrograms. (C)
High-resolution scar voltage map with adjusted threshold and color scale. (D) Electrogram
fractionation; number of intrinsic deflections per electrogram. (E) Late potentials; regions with late
potentials shown in red. (F) VT activation map. All panels display the heart in anterior view (left)
and inferior view (right). In panel A, epicardial breakthrough is indicated by an asterisk “*”,
isochrones are depicted with thin black lines, and black arrows point to conduction block. In panel
F, the VT site of origin is indicated by a plus sign “+”, curved arrows indicate propagation of the
VT wavefront.
The VT site of origin was localized to the dense scar near the inferior base.
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Figure 2-9: Patient #3: VT patient; apical myocardial infarction
(A) Activation isochrone map. (B) Global voltage map; magnitude of unipolar electrograms. (C)
High-resolution scar voltage map with adjusted threshold and color scale. (D) Electrogram
fractionation; number of intrinsic deflections per electrogram. (E) Late potentials; regions with late
potentials shown in red. (F) Single-photon emission computed tomography (SPECT) anatomic scar
in apical view (left) and long-axis view (right); (G) VT activation map. Panels A-E and G display
the heart in apical view (left) and inferior view (right). In panel A, epicardial breakthrough is
indicated by an asterisk “*”, isochrones are depicted with thin black lines, and black arrows point
to conduction block. In panel G, the VT site of origin is indicated by a plus sign “+”, curved arrows
indicate propagation of the VT wavefront.
The VT site of origin was localized to the peripheral scar on the anterior wall near the apex.
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Figure 2-10: Patient #4: VT patient; apical myocardial infarction
(A) Activation isochrone map. (B) Global voltage map; magnitude of unipolar electrograms. (C)
High-resolution scar voltage map with adjusted threshold and color scale. (D) Electrogram
fractionation; number of intrinsic deflections per electrogram. (E) Late potentials; regions with late
potentials shown in red. (F) Single-photon emission computed tomography (SPECT) anatomic scar
in apical view (left) and long-axis view (right); (G) VT activation map. Panels A-E and G display
the heart in anterior view (left) and apical view (right). In panel A, epicardial breakthrough is
indicated by an asterisk “*”, isochrones are depicted with thin black lines, and black arrows point
to conduction block. In panel G, the VT site of origin is indicated by a plus sign “+”, curved arrows
indicate propagation of the VT wavefront.
The VT site of origin was localized to the peripheral scar on the anterior wall near the apex.
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Figure 2-11: Patient #5: VT patient; apical myocardial infarction
(A) Activation isochrone map. (B) Global voltage map; magnitude of unipolar electrograms. (C)
High-resolution scar voltage map with adjusted threshold and color scale. (D) Electrogram
fractionation; number of intrinsic deflections per electrogram. (E) Late potentials; regions with late
potentials shown in red. (F) Single-photon emission computed tomography (SPECT) anatomic scar
in apical view (left) and long-axis view (right); (G) VT activation map. Panels A-E and G display
the heart in anterior view (left) and apical view (right). In panel A, epicardial breakthrough is
indicated by an asterisk “*”, isochrones are depicted with thin black lines, and black arrows point
to conduction block. In panel G, the VT site of origin is indicated by a plus sign “+”, curved arrows
indicate propagation of the VT wavefront.
The VT site of origin was localized to the peripheral scar on the anterior wall near the apex.
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Figure 2-12: Patient #6: VT patient; inferior myocardial infarction
(A) Activation isochrone map. (B) Global voltage map; magnitude of unipolar electrograms. (C)
High-resolution scar voltage map with adjusted threshold and color scale. (D) Electrogram
fractionation; number of intrinsic deflections per electrogram. (E) Late potentials; regions with late
potentials shown in red. (F) Single-photon emission computed tomography (SPECT) anatomic scar
in apical view (left) and long-axis view (right); (G) VT activation map. Panels A-E and G display
the heart in anterior view (left) and inferior view (right). In panel A, epicardial breakthrough is
indicated by an asterisk “*”, isochrones are depicted with thin black lines, and black arrows point
to conduction block. In panel G, the VT site of origin is indicated by a plus sign “+”, curved arrows
indicate propagation of the VT wavefront.
The VT site of origin was localized to the anterior wall near the apex. EGMs with normal voltage
but fractionation and late potentials were found in this region.
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Figure 2-13: Patient #7: VT patient; inferior and infero-lateral myocardial infarction
(A) Activation isochrone map. (B) Global voltage map; magnitude of unipolar electrograms. (C)
High-resolution scar voltage map with adjusted threshold and color scale. (D) Electrogram
fractionation; number of intrinsic deflections per electrogram. (E) Late potentials; regions with late
potentials shown in red. (F) Single-photon emission computed tomography (SPECT) anatomic scar
in apical view (left) and long-axis view (right); (G) VT activation map. Panels A-E and G display
the heart in inferior view (left) and lateral view (right). In panel A, epicardial breakthrough is
indicated by an asterisk “*”, isochrones are depicted with thin black lines, and black arrows point
to conduction block. In panel G, the VT site of origin is indicated by a plus sign “+”, curved arrows
indicate propagation of the VT wavefront.
The VT site of origin was localized to the dense scar near the lateral left ventricular base.
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Figure 2-14: Patient #8: VT patient; anterior myocardial infarction
(A) Activation isochrone map. (B) Global voltage map; magnitude of unipolar electrograms. (C)
High-resolution scar voltage map with adjusted threshold and color scale. (D) Electrogram
fractionation; number of intrinsic deflections per electrogram. (E) Late potentials; regions with late
potentials shown in red. (F) VT activation map. All panels display the heart in anterior view (left)
and lateral view (right). In panel A, epicardial breakthrough is indicated by an asterisk “*”,
isochrones are depicted with thin black lines, and black arrows point to conduction block. In panel
F, the VT site of origin is indicated by a plus sign “+”, curved arrows indicate propagation of the
VT wavefront.
The VT site of origin was localized to the peripheral scar on the anterior wall near the apex.
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Figure 2-15: Patient #9: VT patient; inferior and infero-lateral myocardial infarction
(A) Activation isochrone map. (B) Global voltage map; magnitude of unipolar electrograms. (C)
High-resolution scar voltage map with adjusted threshold and color scale. (D) Electrogram
fractionation; number of intrinsic deflections per electrogram. (E) Late potentials; regions with late
potentials shown in red. All panels display the heart in anterior view (left) and lateral view (right).
In panel A, epicardial breakthrough is indicated by an asterisk “*”, isochrones are depicted with thin
black lines, and black arrows point to conduction block.
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Figure 2-16: Patient #10: VT patient; inferior and apical myocardial infarction
(A) Activation isochrone map. (B) Global voltage map; magnitude of unipolar electrograms. (C)
High-resolution scar voltage map with adjusted threshold and color scale. (D) Electrogram
fractionation; number of intrinsic deflections per electrogram. (E) Late potentials; regions with late
potentials shown in red. (F) Single-photon emission computed tomography (SPECT) anatomic scar
in apical view (left) and long-axis view (right). Panels A-E display the heart in anterior view (left)
and inferior view (right). In panel A, epicardial breakthrough is indicated by an asterisk “*”,
isochrones are depicted with thin black lines, and black arrows point to conduction block.
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Figure 2-17: Patient #11: VT patient; anterior and apical myocardial infarction
(A) Activation isochrone map. (B) Global voltage map; magnitude of unipolar electrograms. (C)
High-resolution scar voltage map with adjusted threshold and color scale. (D) Electrogram
fractionation; number of intrinsic deflections per electrogram. (E) Late potentials; regions with late
potentials shown in red. All panels display the heart in anterior view (left) and inferior view (right).
In panel A, epicardial breakthrough is indicated by an asterisk “*”, isochrones are depicted with thin
black lines, and black arrows point to conduction block.
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Figure 2-18: Patient #12: VT patient; anterior and apical myocardial infarction
(A) Activation isochrone map. (B) Global voltage map; magnitude of unipolar electrograms. (C)
High-resolution scar voltage map with adjusted threshold and color scale. (D) Electrogram
fractionation; number of intrinsic deflections per electrogram. (E) Late potentials; regions with late
potentials shown in red. All panels display the heart in anterior view (left) and lateral view (right).
In panel A, epicardial breakthrough is indicated by an asterisk “*”, isochrones are depicted with thin
black lines, and black arrows point to conduction block.
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Figure 2-19: Patient #13: VT patient; anterior, lateral and inferior myocardial infarction
(A) Activation isochrone map. (B) Global voltage map; magnitude of unipolar electrograms. (C)
High-resolution scar voltage map with adjusted threshold and color scale. (D) Electrogram
fractionation; number of intrinsic deflections per electrogram. (E) Late potentials; regions with late
potentials shown in red. (F) Single-photon emission computed tomography (SPECT) anatomic scar
in apical view (left) and long-axis view (right). Panels A-E display the heart in inferior view (left)
and lateral view (right). In panel A, isochrones are depicted with thin black lines, and black arrows
point to conduction block.
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Figure 2-20: Patient #14: VT patient; anterior myocardial infarction
(A) Activation isochrone map. (B) Global voltage map; magnitude of unipolar electrograms. (C)
High-resolution scar voltage map with adjusted threshold and color scale. (D) Electrogram
fractionation; number of intrinsic deflections per electrogram. (E) Late potentials; regions with late
potentials shown in red. All panels display the heart in anterior view (left) and lateral view (right).
In panel A, epicardial breakthrough is indicated by an asterisk “*”, isochrones are depicted with thin
black lines, and black arrows point to conduction block.
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Figure 2-21: Patient #15: VT patient; lateral, inferior and apical myocardial infarction
(A) Activation isochrone map. (B) Global voltage map; magnitude of unipolar electrograms. (C)
High-resolution scar voltage map with adjusted threshold and color scale. (D) Electrogram
fractionation; number of intrinsic deflections per electrogram. (E) Late potentials; regions with late
potentials shown in red. (F) Single-photon emission computed tomography (SPECT) anatomic scar
in apical view (left) and long-axis view (right). Panels A-E display the heart in inferior view (left)
and apical view (right). In panel A, epicardial breakthrough is indicated by an asterisk “*”,
isochrones are depicted with thin black lines, and black arrows point to conduction block.
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Figure 2-22: Patient #16: VT patient; anterior and apical myocardial infarction
(A) Activation isochrone map. (B) Global voltage map; magnitude of unipolar electrograms. (C)
High-resolution scar voltage map with adjusted threshold and color scale. (D) Electrogram
fractionation; number of intrinsic deflections per electrogram. (E) Late potentials; regions with late
potentials shown in red. All panels display the heart in anterior view (left) and lateral view (right).
In panel A, epicardial breakthrough is indicated by an asterisk “*”, isochrones are depicted with thin
black lines, and black arrows point to conduction block.
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Figure 2-23: Patient #17: VT patient; inferior and apical myocardial infarction
(A) Activation isochrone map. (B) Global voltage map; magnitude of unipolar electrograms. (C)
High-resolution scar voltage map with adjusted threshold and color scale. (D) Electrogram
fractionation; number of intrinsic deflections per electrogram. (E) Late potentials; regions with late
potentials shown in red. All panels display the heart in anterior view (left) and inferior view (right).
In panel A, epicardial breakthrough is indicated by an asterisk “*”, isochrones are depicted with thin
black lines, and black arrows point to conduction block.
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2.7.2

Maps of EP Substrate for Non-VT Patients

Figure 2-24: Patient #18: Non-VT patient; inferior myocardial infarction
(A) Activation isochrone map. (B) Global voltage map; magnitude of unipolar electrograms. (C)
High-resolution scar voltage map with adjusted threshold and color scale. (D) Electrogram
fractionation; number of intrinsic deflections per electrogram. (E) Late potentials; regions with late
potentials shown in red. All panels display the heart in anterior view (left) and inferior view (right).
In panel A, epicardial breakthrough is indicated by an asterisk “*”, isochrones are depicted with thin
black lines, and black arrows point to conduction block.
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Figure 2-25: Patient #19: Non-VT patient; apical, inferior and infero-lateral myocardial
infarction
(A) Activation isochrone map. (B) Global voltage map; magnitude of unipolar electrograms. (C)
High-resolution scar voltage map with adjusted threshold and color scale. (D) Electrogram
fractionation; number of intrinsic deflections per electrogram. (E) Late potentials; regions with late
potentials shown in red. All panels display the heart in anterior view (left) and inferior view (right).
In panel A, epicardial breakthrough is indicated by an asterisk “*”, isochrones are depicted with thin
black lines.
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Figure 2-26: Patient #20: Non-VT patient; apical and inferior myocardial infarction
(A) Activation isochrone map. (B) Global voltage map; magnitude of unipolar electrograms. (C)
High-resolution scar voltage map with adjusted threshold and color scale. (D) Electrogram
fractionation; number of intrinsic deflections per electrogram. (E) Late potentials; regions with late
potentials shown in red. (F) Single-photon emission computed tomography (SPECT) anatomic scar
in apical view (left) and long-axis view (right). Panels A-E display the heart in anterior view (left)
and inferior view (right). In panel A, epicardial breakthrough is indicated by an asterisk “*”,
isochrones are depicted with thin black lines, and black arrows point to conduction block.
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Figure 2-27: Patient #21: Non-VT patient; inferior myocardial infarction
(A) Activation isochrone map. (B) Global voltage map; magnitude of unipolar electrograms. (C)
High-resolution scar voltage map with adjusted threshold and color scale. (D) Electrogram
fractionation; number of intrinsic deflections per electrogram. (E) Late potentials; regions with late
potentials shown in red. All panels display the heart in anterior view (left) and inferior view (right).
In panel A, epicardial breakthrough is indicated by an asterisk “*”, isochrones are depicted with thin
black lines, and black arrows point to conduction block.
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Figure 2-28: Patient #22: Non-VT patient; inferior myocardial infarction
(A) Activation isochrone map. (B) Global voltage map; magnitude of unipolar electrograms. (C)
High-resolution scar voltage map with adjusted threshold and color scale. (D) Electrogram
fractionation; number of intrinsic deflections per electrogram. (E) Late potentials; regions with late
potentials shown in red. (F) Single-photon emission computed tomography (SPECT) anatomic scar
in apical view (left) and long-axis view (right). Panels A-E display the heart in anterior view (left)
and inferior view (right). In panel A, epicardial breakthrough is indicated by an asterisk “*”,
isochrones are depicted with thin black lines, and black arrows point to conduction block.
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Figure 2-29: Patient #23: Non-VT patient; apical and inferior myocardial infarction
(A) Activation isochrone map. (B) Global voltage map; magnitude of unipolar electrograms. (C)
High-resolution scar voltage map with adjusted threshold and color scale. (D) Electrogram
fractionation; number of intrinsic deflections per electrogram. (E) Late potentials; regions with late
potentials shown in red. (F) Single-photon emission computed tomography (SPECT) anatomic scar
in apical view (left) and long-axis view (right). Panels A-E display the heart in anterior view (left)
and inferior view (right). In panel A, epicardial breakthrough is indicated by an asterisk “*”,
isochrones are depicted with thin black lines, and black arrows point to conduction block.
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Figure 2-30: Patient #24: Non-VT patient; apical and inferior myocardial infarction
(A) Activation isochrone map. (B) Global voltage map; magnitude of unipolar electrograms. (C)
High-resolution scar voltage map with adjusted threshold and color scale. (D) Electrogram
fractionation; number of intrinsic deflections per electrogram. (E) Late potentials; regions with late
potentials shown in red. (F) Single-photon emission computed tomography (SPECT) anatomic scar
in apical view (left) and long-axis view (right). Panels A-E display the heart in anterior view (left)
and inferior view (right). In panel A, epicardial breakthrough is indicated by an asterisk “*”,
isochrones are depicted with thin black lines, and black arrows point to conduction block.

53

Figure 2-31: Patient #25: Non-VT patient; apical myocardial infarction
(A) Activation isochrone map. (B) Global voltage map; magnitude of unipolar electrograms. (C)
High-resolution scar voltage map with adjusted threshold and color scale. (D) Electrogram
fractionation; number of intrinsic deflections per electrogram. (E) Late potentials; regions with late
potentials shown in red. (F) Single-photon emission computed tomography (SPECT) anatomic scar
in apical view (left) and long-axis view (right). Panels A-E display the heart in anterior view (left)
and apical view (right). In panel A, epicardial breakthrough is indicated by an asterisk “*”,
isochrones are depicted with thin black lines, and black arrows point to conduction block.
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Figure 2-32: Patient #26: Non-VT patient; inferior myocardial infarction
(A) Activation isochrone map. (B) Global voltage map; magnitude of unipolar electrograms. (C)
High-resolution scar voltage map with adjusted threshold and color scale. (D) Electrogram
fractionation; number of intrinsic deflections per electrogram. (E) Late potentials; regions with late
potentials shown in red. All panels display the heart in anterior view (left) and inferior view (right).
In panel A, epicardial breakthrough is indicated by an asterisk “*”, isochrones are depicted with thin
black lines, and black arrows point to conduction block.
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Figure 2-33: Patient #27: Non-VT patient; inferior myocardial infarction
(A) Activation isochrone map. (B) Global voltage map; magnitude of unipolar electrograms. (C)
High-resolution scar voltage map with adjusted threshold and color scale. (D) Electrogram
fractionation; number of intrinsic deflections per electrogram. (E) Late potentials; regions with late
potentials shown in red. (F) Single-photon emission computed tomography (SPECT) anatomic scar
in apical view (left) and long-axis view (right). Panels A-E display the heart in anterior view (left)
and inferior view (right). In panel A, epicardial breakthrough is indicated by an asterisk “*”,
isochrones are depicted with thin black lines, and black arrows point to conduction block.
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Figure 2-34: Patient #28: Non-VT patient; apical myocardial infarction
(A) Activation isochrone map. (B) Global voltage map; magnitude of unipolar electrograms. (C)
High-resolution scar voltage map with adjusted threshold and color scale. (D) Electrogram
fractionation; number of intrinsic deflections per electrogram. (E) Late potentials; regions with late
potentials shown in red. All panels display the heart in anterior view (left) and inferior view (right).
In panel A, epicardial breakthrough is indicated by an asterisk “*”, isochrones are depicted with thin
black lines, and black arrows point to conduction block.
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Figure 2-35: Patient #29: Non-VT patient; inferior myocardial infarction
(A) Activation isochrone map. (B) Global voltage map; magnitude of unipolar electrograms. (C)
High-resolution scar voltage map with adjusted threshold and color scale. (D) Electrogram
fractionation; number of intrinsic deflections per electrogram. (E) Late potentials; regions with late
potentials shown in red. (F) Single-photon emission computed tomography (SPECT) anatomic scar
in apical view (left) and inferior view (right). Panels A-E display the heart in anterior view (left)
and inferior view (right). In panel A, epicardial breakthrough is indicated by an asterisk “*”,
isochrones are depicted with thin black lines, and black arrows point to conduction block.
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Figure 2-36: Patient #30: Non-VT patient; anterior, apical and inferior myocardial infarction
(A) Activation isochrone map. (B) Global voltage map; magnitude of unipolar electrograms. (C)
High-resolution scar voltage map with adjusted threshold and color scale. (D) Electrogram
fractionation; number of intrinsic deflections per electrogram. (E) Late potentials; regions with late
potentials shown in red. (F) Single-photon emission computed tomography (SPECT) anatomic scar
in apical view (left) and long-axis view (right). Panels A-E display the heart in anterior view (left)
and inferior view (right). In panel A, epicardial breakthrough is indicated by an asterisk “*”,
isochrones are depicted with thin black lines, and black arrows point to conduction block.
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Figure 2-37: Patient #31: Non-VT patient; anterior and apical myocardial infarction
(A) Activation isochrone map. (B) Global voltage map; magnitude of unipolar electrograms. (C)
High-resolution scar voltage map with adjusted threshold and color scale. (D) Electrogram
fractionation; number of intrinsic deflections per electrogram. (E) Late potentials; regions with late
potentials shown in red. (F) Single-photon emission computed tomography (SPECT) anatomic scar
in apical view (left) and long-axis view (right). Panels A-E display the heart in anterior view (left)
and apical view (right). In panel A, epicardial breakthrough is indicated by an asterisk “*”,
isochrones are depicted with thin black lines, and black arrows point to conduction block.
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Figure 2-38: Patient #32: Non-VT patient; anterior and apical myocardial infarction
(A) Activation isochrone map. (B) Global voltage map; magnitude of unipolar electrograms. (C)
High-resolution scar voltage map with adjusted threshold and color scale. (D) Electrogram
fractionation; number of intrinsic deflections per electrogram. (E) Late potentials; regions with late
potentials shown in red. All panels display the heart in anterior view (left) and lateral view (right).
In panel A, epicardial breakthrough is indicated by an asterisk “*”, isochrones are depicted with thin
black lines, and black arrows point to conduction block.
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2.7.3

Video Files (available in the attached CD): ECGI Activation Movies
Movie 2-1: The activation sequence during VT for patient #3.
Movie 2-2: The activation sequence during VT for patient #8.
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Chapter 3:

The

Electrophysiological

Substrate

of

Early

Repolarization Syndrome: Noninvasive Mapping in Patients
3.1

Abstract
The early repolarization (ER) pattern is a common ECG finding. Recent studies established

a definitive clinical association between ER and fatal ventricular arrhythmias. Although the
underlying mechanisms have been studied at the cellular level, the arrhythmogenic substrate in the
intact human heart remains poorly understood.
Using noninvasive Electrocardiographic Imaging (ECGI), we studied 29 ER syndrome
patients to characterize the electrophysiological (EP) substrate. Seven normal subjects provided
control data. The abnormal EP substrate in ER syndrome patients has the following properties: (1)
Abnormal epicardial EGMs characterized by presence of J-waves; (2) Absence of conduction
abnormalities, including delayed activation, conduction block, or low-voltage and fractionated
electrograms; (3) Marked abbreviation of ventricular repolarization in areas with epicardial Jwaves. The action potential duration (APD) was significantly shorter than normal (196±19 vs.
235±21 ms, p<0.05). Shortening of APD occurred heterogeneously, leading to steep repolarization
gradients compared to normal control (45±17 vs.7±5 ms/cm, p<0.05). Premature ventricular
contractions (PVCs) were recorded in 2 patients. The PVC sites of origin were closely associated
with the abnormal EP substrate with J-waves and steep repolarization gradients.
ECGI identifies regions with steep repolarization gradients caused by localized shortening
of APD in ER syndrome patients. It also correlates the PVC initiation site with the abnormal EP
substrate.

63

3.2

Introduction
The early repolarization (ER) pattern on the ECG is characterized by a J-wave >= 0.1 mV

in inferior and/or lateral leads.48-50 It resolves during exercise and fast pacing, but accentuates
during bradycardia. The prevalence of ER pattern in the general population is estimated to range
between 1% and 13%.48-49, 51 It is thought to be more common in males, young athletes and people
of African descent.
Early descriptions of the ER pattern came from cases of hypothermia and hypercalcermia.
For decades, the ER pattern was recognized as a benign ECG manifestation.52 Since the 1980s,
this view has been challenged by animal experiments50, 53, case reports54-57 and review articles58-59
that linked the ER pattern with ventricular arrhythmia. In a recent study with a large cohort of
patients, the prevalence of ER pattern was significantly higher in patients with idiopathic
ventricular fibrillation (VF) compared to control subjects.60 This was the first study that provided
clinical evidence supporting a definitive association between the ER pattern and an increased risk
of ventricular arrhythmia. Following this study, additional population-based studies provided
corroborating evidences.49,

61-65

The critical role of the ER pattern in initiating ventricular

fibrillation has been supported by observations of a consistent and marked J-wave accentuation
preceding the onset of arrhythmia60, 66 and by electrophysiology (EP) mapping data that showed a
consistency between the origin of ectopy that initiated VF and the localization of repolarization
abnormalities.60
ER has been extensively studied at the molecular and cellular levels.50, 67 Based on the
prevailing theory, the notch at phase-1 of the epicardial action potential (AP) is more prominent
than that of the endocardial AP. The transmural voltage gradients give rise to the J-wave on the
ECG. Further outward shift of the currents can cause loss of the AP plateau. Spatially
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heterogeneous loss of the AP plateau can lead to reentry (termed “phase-2 reentry”).68 However,
limitations apply to this model. Extrapolation from cellular processes to tissue and organ behavior
is difficult, because information at the molecular level is not sufficient to predict and understand
the complex integrated behavior at higher levels of the physiological system. In particular,
information on the electrophysiology and arrhythmic behaviors of the intact human heart in vivo,
where arrhythmias occur, is missing.
Studies in patients with ER syndrome (ERS) have been so far confined to investigation of
the ECG characteristics and extrapolating possible mechanisms. However, ECG characteristics
have been shown to be inadequate measures of underlying repolarization properties.7 Reports of
EP mapping in patients with ERS provide limited information about the abnormal EP substrate.60,
69-70

Understanding the mechanism of ER and how it may predispose patients to an increased risk

of arrhythmias requires detailed mapping of the EP substrate in the intact heart of ERS patients.
Recent developments in noninvasive Electrocardiographic Imaging

1, 6-7, 10, 13, 16-17

(ECGI; also

known as ECG mapping, ECM) have demonstrated its ability to obtain high-resolution panoramic
EP data of epicardial activation, repolarization and their alteration by disease and interventions in
humans. In the current study, we characterize the epicardial EP substrate in ERS patients based on
high-resolution ECGI data obtained during sinus rhythm (SR), in an effort to provide insights into
the mechanism of ER and related arrhythmogenesis.

3.3
3.3.1

Methods
Patient Population
ERS patients from one center in the United States (Washington University) and one center

in France (Bordeaux University Hospital) were enrolled. The clinical diagnosis is ER pattern on
the ECG, defined as an elevation of the J-point (J-wave) in at least two leads. The J-wave is
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manifested either as QRS slurring (a smooth transition from the QRS complex to the ST segment)
or QRS notching (a positive deflection inscribed on the S wave) in the inferior lead, lateral lead,
or both. The patients should have at least one of the following: idiopathic ventricular tachycardia
(VT) or VF, unexplained syncope and familial incidence of unexplained sudden cardiac death.
Patients with ischemic heart disease and other conditions including long QT syndrome, short QT
syndrome, Brugada syndrome (BrS) and arrhythmogenic right ventricular cardiomyopathy were
excluded. All patients had structurally normal hearts and normal ventricular function. Data from
seven normal subjects provided normal control.13 Protocols were approved by the Institutional
Review Boards at both centers; written informed consent was obtained from all patients.
3.3.2

Noninvasive Mapping
Details of ECGI methodology were described previously.

1, 6-7, 10, 13, 16-17

Body surface

potentials were acquired simultaneously using 256 electrodes and a multichannel mapping system.
Next, the patient underwent thoracic computer tomography with ECG-gating to obtain the
epicardial geometry and torso electrode positions. The body surface potentials and the patientspecific heart-torso geometry were processed with ECGI algorithms to reconstruct epicardial
potentials, unipolar electrograms (EGMs), and maps of epicardial activation and repolarization.
ECGI has been validated extensively in canine experiments and humans studies. It provides high
accuracy and high-resolution (2 to 6 mm) panoramic data for noninvasive evaluation of EP
properties.12
3.3.3

Data Analysis
Characteristics of the abnormal EP substrate in ERS patients were analyzed by using data

recorded during sinus rhythm. The EP mapping data were analyzed for EGM morphology,
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conduction and repolarization. The ER pattern on epicardial EGMs was defined as J-point
elevation at the end of QRS. The size of the epicardium with J-waves in the EGMs was measured
as well (as a percentage of total epicardial surface area). Conduction was evaluated by activation
time (AT), activation duration (AD), EGM fractionation and voltage. AT was determined by the
maximal negative slope of the EGM during QRS inscription. All ATs were referenced to the
beginning of QRS in ECG lead II. Epicardial activation isochrone maps were created from ATs.
AD was defined as the interval between the earliest and latest AT, considering all epicardial EGMs.
EGMs with low voltage and fractionation indicate slow, discontinuous and non-uniform
conduction. EGM magnitude was measured peak-to-peak during the EGM QRS. Fractionation was
expressed as the number of intrinsic, sharp deflections per EGM. Repolarization was assessed by
recovery time (RT) and activation-recovery interval (ARI). Local RT was determined from the
maximal positive slope of the EGM T-wave, which reflects the sum of local AT and local action
potential duration (APD). Steep RT dispersion has been shown to provide substrate for
unidirectional block and reentry. ARI was defined as the difference between RT and AT. ARI is
independent of AT and a surrogate for local APD.71 From the RT map and ARI map, epicardial
dispersion of repolarization was measured as the maximal difference ΔRT and ΔARI between two
adjacent EGM sites on the epicardium. Epicardial RT and ARI gradients (ΔRT/Δx and ΔARI/Δx)
were computed through division by the distance Δx between the two adjacent sites.

3.3.4

Statistical Analysis:
All continuous data are presented as mean±SD. Continuous variables were analyzed by

unpaired t-test. The Satterthwaite modified t-test was used for variables with unequal variances.
The Mann-Whitney U test was used for variables with non-normal distribution. All tests with
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P<0.05 were considered statistically significant. Statistical analysis was performed by using SPSS
v19.
Previously
Family
Aborted
History
Patient
ICD
Age Gender
SCD/
Syncope
of
ID
Implant
Documented
SCD/
VT or VF
ERS

ECG Leads with ER
Inferior
Leads

Lateral
Leads

ER-1

27

M

+

-

+

+

ER-2

60

F

-

64

M

+
-

+

ER-3

+

II, III,
aVF
II, III

-

+

II

ER-4

24

M

+

+

-

+

ER-5

49

M

+

-

-

-

ER-6

23

M

-

+

-

-

ER-7

59

M

+

-

-

+

ER-8

24

M

-

-

+

-

ER-9

48

F

+

25

M

+
+

+

ER-10

+
-

-

-

ER-11

31

M

-

-

+

-

ER-12

28

M

+

+

+

+

ER-13

25

M

+

-

+

-

ER-14

37

M

+

-

-

-

ER-15

35

M

-

+

-

-

ER-16

34

M

+

+

-

-

ER-17

65

M

-

-

+

-

ER-18

41

M

-

V4, V5

48

M

-

-

V5, V6

ER-20

27

M

-

-

II, III

ER-21

24

M

-

-

II

ER-22

58

M

+
+
+
-

-

ER-19

+
+

-

+
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II
II, III,
aVF
II, aVF
II, III,
aVF

V4, V5, V6

I, V5, V6
I, V4, V5,
V6
I
V4, V5, V6
V4, V5, V6
V5, V6
V5, V6

II

V5, V6
V4, V5, V6

II, III,
aVF
II, aVF
II, III,
aVF
II, III,
aVF
II
II, III,
aVF

V5, V6
I, V4, V5,
V6
V4, V5, V6
I, V5, V6
V4, V5

V5, V6
V4, V5

ER-23

49

M

+

+

-

+

ER-24

21

M

+

-

-

-

ER-25

40

M

+

+

-

-

ER-26

26

F

-

+

-

-

ER-27

31

M

-

-

+

-

ER-28

23

M

+

-

+

+

ER-29

22

M

+

-

-

+

II, III,
aVF
II, III,
aVF
II, III
II, III,
aVF
II, III,
aVF
II, III,
aVF

V4, V5, V6
I, V4, V5,
V6
I, V4, V5,
V6
V4, V5, V6
V5, V6

V4, V5, V6

Table 3-1: Clinical Characteristics of the ERS Patients

3.4

Results:
Twenty-nine ERS patients (26 men, 3 women) were enrolled in this study. Seventeen

(59%) had previous aborted SCD or arrhythmic events (idiopathic VT/VF), 10 of which received
implantable cardioverter-defibrillator (ICD). Fourteen (48%) experienced unexplained syncope.
Ten (34%) had a family history of SCD or ERS. Detailed characteristics for individual patient are
provided in Table 3-1.
3.4.1

EGM Characterization and Localization
Figure 3-1 shows epicardial EGM characteristics and localization for representative

examples in 3 ERS patients. Patient ER-11 was an asymptomatic patient with a family history of
sudden death. He had ER pattern in lateral leads. Patient ER-14 experienced previously aborted
sudden death, and had ER pattern in inferior leads and lateral leads. Patient ER-20 did not have
clinical arrhythmic events, but experienced unexplained syncope. His ER pattern was found in
inferior leads. Data from a normal subject is provided for reference. Epicardial J-wave was
observed in EGMs from all 25 ERS patients (0.68±0.25 mV vs. 0 mV in control, p<0.05); 6 in the
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anterior wall, 19 in the lateral wall and 23 in the inferior wall (most patients had epicardial J-wave
in multiple locations). The proportion of epicardium that presented J-wave ranges from 23% to
57%, with a mean value of 39%±9%. EGMs with abnormal low-voltage and fractionation were
not found in any ERS patient.

Figure 3-1: Epicardial J-wave Distribution and Magnitude
Abnormal epicardial EGMs with a J-wave that resemble the ER pattern (terminal-QRS notch or
slurring) on the surface ECG are observed in ERS patients, but not seen in normal subjects.
Example maps of epicardial J-wave magnitude in 3 ERS patients are shown. The maps are shown
in anterior view and inferior view for each subject. The locations of epicardial J-waves are ER11: lateral and apical left ventricle (LV); ER-14: lateral and inferior LV; ER-20: lateral and
inferior LV. Inset: representative EGMs with a J-wave (QRS only) in ERS patients (Panels B,
C, D) and EGMs from corresponding locations in the normal control subject (Panel A). LA =
left atrium; LV = left ventricle; RA = right ventricle; RV = right ventricle.
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Figure 3-2: Activation Isochrone Maps
Examples of activation during sinus rhythm (SR) are shown for a normal control subject and 3
ERS patients. The maps are shown in anterior view and inferior view for each subject. ERS
patients and the normal subject have similar activation patterns. After breakthrough in the
anterior right ventricle (asterisk), the wavefront propagates uniformly to activate both ventricles.
The LV base is the latest region to activate. Conduction block and slow conduction were not
observed in the ERS patients.

3.4.2

Epicardial Activation
Figure 3-2 shows ECGI epicardial activation isochrone maps for a control subject and 3

ERS patients (same patients as in Figure 3-1). The epicardial activation pattern during SR in ERS
patients was characterized by a normal epicardial breakthrough (white asterisks) in the right
ventricle (RV). The excitation wavefront spread uniformly and rapidly to activate both ventricles.
The left ventricular (LV) base was the latest region to activate. The activation pattern was not
affected by the presence of the J-wave: regions of slow conduction (isochrone crowding) or
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conduction block (adjacent activation times differ by more than 50 ms) were not found in ERS
patients. A similar activation sequence was observed in the normal control subjects, as well as in
the isolated human heart from individuals with no history of cardiac disease.72 AD, the time needed
for activation of both ventricles, was 54±7 ms for ERS patients, comparable with 47±9 ms for
normal control.

Figure 3-3: Recovery Time (RT) Maps
Examples of epicardial RT during SR are shown for a normal control subject and 3 ERS patients.
Maps are shown in anterior view and inferior view for each subject. ERS patients have regions
with abnormally short RT (dark blue). White arrows in Panels B-C point to regions with steep
RT gradients.
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Figure 3-4: Activation-recovery Interval (ARI) Maps
Panels A to D: ARI maps for a normal control subject and 3 ERS patients. Maps are shown in
anterior view and inferior view for each subject. ERS patients have regions with abnormally short
ARI (dark blue). White arrows in Panels B-C point to regions with steep ARI gradients. Panel E
shows the ECGI reconstructed electrograms (EGMs) from two adjacent locations for each ERS
patient. Location 1: prominent J-wave and short ARI; location 2: absence of J-wave and normal
ARI. There is a steep gradient of repolarization across these two locations. The time instances of
activation (AT; black square), recovery (RT; red square) and corresponding ARIs are indicated.
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3.4.3

Epicardial Repolarization
Representative maps of RT (Figure 3-3) and ARI (Figure 3-4) from a normal subject and

3 ERS patients (same patients as in Figure 3-1) demonstrate marked local changes in repolarization
in ERS patients compared with normal control. Abnormal repolarization was observed primarily
in regions with a prominent J-wave. Steep epicardial RT gradients and ARI gradients occurred
mostly at the border of regions where J-wave were present (Figure 3-3, Panel B-D, white arrows).
Figure 3-4E shows EGMs with prominent J-wave (location 1) and EGMs without J-wave from an
adjacent location (location 2) for 3 ER patients. Take patient ER-11 for example, ATs at location
1 and 2 were similar (AT(1) =66 ms, AT(2) =61 ms), but repolarization dispersion was observed
between the two locations: ΔRT was 65 ms (RT(1) =232 ms, RT(2) =297 ms) and ΔARI was 70
ms (ARI(1) =166 ms, ARI(2) =236 ms). This resulted in steep gradients of RT and ARI (ΔRT/Δx
=43 ms/cm; ΔARI/Δx =46 ms/cm), much steeper than those of control (typically 5~8 ms/cm and
4~10 ms/cm, respectively, in the same region). Patients ER-14 and ER-20 also had shortened RT
and ARI, as well as increased gradients of RT and ARI, but the location of abnormal repolarization
varied.
Table 3-2 summarizes the ECGI-derived parameters. Compared with normal control, ERS
patients had shortened RT (223±28 vs. 265±30 ms, p<0.05) and ARI (196±19 vs. 235±21 ms,
p<0.05), increased repolarization dispersion ΔRT (52±15 vs.18±14 ms, p<0.05) and ΔARI (53±15
vs. 16±10 ms, p<0.05) and increased repolarization gradients ΔRT/Δx (48±18 vs. 8±6 ms/cm,
p<0.05 ) and ΔARI/Δx (45±17 vs. 7±5 ms/cm, p<0.05).
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Normal

ERS Patients

P

(N=29)

value

0

0.68±0.25

P<0.05

AD (ms)

47±9

54±7

NS

Mean RT (ms)

265±30

223±28

P<0.05

ΔRT (ms)

18±14

52±15

P<0.05

ΔRT/Δx (ms/cm)

8±6

48±18

P<0.05

Mean ARI (ms)

235±21

196±19

P<0.05

ΔARI (ms)

16±10

53±15

P<0.05

ΔARI/Δx (ms/cm)

7±5

45±17

P<0.05

Parameters

Control
(N=7)

J-wave Magnitude
(mV)

Table 3-2: Comparison of ECGI Parameters between ERS Patients and Normal Subjects
Data are presented as mean±SD. AD = activation duration; ARI = activation-recovery interval; RT
= recovery time; NS = not significant.

3.4.4

Ventricular Arrhythmias
Premature ventricular contractions (PVCs) were recorded in two patients, ER-1 and ER-

11. Figure 3-5 shows substrate maps (J-wave and ARI) and PVC activation maps for patients ER1 and ER-11. Panel A shows that in patient ER-1, a large portion of epicardium (54%) was affected
by abnormal EGMs with J-waves, including anterior RV, anterior LV, lateral LV, apical LV and
inferior LV (not shown). In patient ER-11, about 32% of the epicardium had J-waves in the EGMs,
located in the antero-lateral and apical LV. Panel B shows that in patient ER-1, the anterior RV
had the shortest ARI (about 140 ms), and the majority of LV had ARI less than 180 ms,
significantly below the normal range. Patient ER-11 had shortened ARI (about 160 ms) in the
antero-lateral and apical LV. Panel C shows the PVC activation patterns. In patient ER-1, the PVC
originated from the apical LV region, then propagated towards the basal RV. In patient ER-11, the
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PVC initiation site was located in mid anterior LV near the septum. The inferior LV was the latest
region to activate during a PVC. In both cases, locations of the EP substrate with abnormal EGMs,
shortened ARIs and steep ARI gradients correlated with the PVC sites of origin.

Figure 3-5: The electrophysiological substrate in relation to premature ventricular
contractions (PVCs)
Panel A: Epicardial J-wave magnitude and Panel B: Activation-recovery interval (ARI) maps
during SR. Panel C: PVC activation map. Each panel shows the maps for 2 patients, ER-1 (left)
and ER-11 (right). The hearts are displayed in anterior view and lateral view. Inset: abnormal
electrograms (EGMs) with J-waves during SR from the PVC sites of origin. The PVC initiation
sites are indicated by plus signs “+”. Note that an EP substrate with abnormal EGMs, shortened
ARIs and steep ARI gradients correlated with the PVC site of origin in both cases.
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3.5

Discussion:
This is the first noninvasive mapping study in ERS patients that identifies key epicardial

EP properties that may account for the arrhythmogenicity in this syndrome. High-resolution
panoramic mapping was essential for characterizing the properties of the EP substrate; it was made
possible by noninvasive ECGI. The results indicate that ERS patients present with regions of
abnormal EP substrate with the following properties: (1) Abnormal epicardial EGMs characterized
by the presence of a J-wave, which is consistent with the ECG-based clinical phenotype; (2)
Absence of conduction abnormalities, such as delayed activation, EGMs with low voltage and
fractionation; (3) Marked abbreviation of ventricular repolarization in areas with epicardial Jwaves, leading to steep repolarization gradients.
The cellular mechanisms underlying the ER pattern and arrhythmogenesis have been
studied using canine ventricular wedge preparation.67-68 Because the expression of transient
outward current (Ito) is highest in the epicardium and diminishes transmurally towards the
endocardium, a phase-1 notch is present in epicardial AP, but not in endocardial AP. The
transmural voltage gradient during an early phase of ventricular repolarization registers as J-wave
on the ECG. Under pathological conditions, in the presence of an intense Ito or with a greater
outward shift of currents active at the end of phase 1 of the AP (increase in IK-ATP, IK-ACh or decrease
in ICa-L or late INa), the membrane is repolarized prematurely, losing the epicardial AP plateau,
which leads to marked abbreviation of the AP. The loss of the AP plateau in epicardium but not
endocardium creates transmural voltage gradients during phase 2 and 3 of the AP that manifest as
a prominent ST-segment elevation.50 Spatially heterogeneous loss of the AP plateau can generate
substrate with steep repolarization gradients that may facilitate the development of phase 2 reentry
and polymorphic VT/VF.68 A recent study in a canine LV wedge preparation showed that
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accentuation of the AP notch in the LV epicardium gave rise to the ER pattern.73 This
repolarization abnormality was accentuated by increased vagal tone, and normalized by
administration of isoproterenol and quinidine. The levels of Ito was higher in the inferior LV wall,
which may account for the greater sensitivity to development of VT/VF in this region.
Since the link between the ER pattern on the ECG and fatal cardiac arrhythmias has been
confirmed,60 numerous studies have been conducted in an effort to stratify risks of ventricular
arrhythmias in the ER population. Risk stratification has profound clinical importance, given the
prevalence of the ER pattern in the general population. Importantly, young otherwise healthy
individuals with ER may be more vulnerable to idiopathic VF.74-75 Currently, surface ECG is the
only tool available and the identification of ERS patients at risk remains extremely challenging.
Surface ECG markers, including the amplitude and distribution of the J-wave, morphology of the
ST segment and the presence of ventricular ectopy have been demonstrated to predict arrhythmic
risks. A higher J-wave amplitude is associated with increased risk of sudden death.49, 65 A lateral
distribution of ER does not portend risk, whereas an inferior and global distribution of ER predicts
an increased risk of arrhythmic death.49, 60, 63 A horizontal or descending ST segment also portends
a higher risk of sudden death.65, 76-77 Of note, although these ECG markers are associated with an
increased relative risk of arrhythmia in the ER population, they have very limited utility in
predicting the absolute risk in the general population, due to the extraordinarily low incidence of
idiopathic VF.78 A recent study investigated the role of EP studies in risk stratification in ERS
patients.79 Results indicate that VF inducibility does not have a role in risk stratification in ERS
patients; it neither predicts arrhythmic risks, nor correlates with the ECG markers discussed earlier.
Better understanding of the clinical entity is the key for development of diagnostic and risk
stratification tools.
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The fact that a significant number of individuals with ERS had a family history of sudden
cardiac death suggests a genetic basis for this syndrome. ERS has been associated with mutations
in 7 genes, including mutations in KCNJ8 and ABCC9 that encode the IK-ATP channel,80-82
mutations in CACNA1C, CACNB2 and CACNA2D1 associated with the ICa-L channel,83 and a
mutation in SCN5A that affects INa.84 Interestingly, the IK-ATP channel is inactive in non-ischemic
ventricular myocardium; it activates and becomes increasingly outward with decreasing levels of
ATP.85 IK-ATP is expressed in myocytes at very high levels, similar to that of INa.86-87 Experimental
and simulation studies consistently showed that opening of a small percentage of IK-ATP channels
(0.7% -1.2%) may shorten the APD by 50%.86, 88 Mutations can cause IK-ATP channels to open at
normal ATP levels, thereby causing early AP repolarization. As discussed above, heterogeneous
APD abbreviation can provide both the substrate and trigger that precipitate VF.
The current study investigated whether the electrocardiographic manifestation of ER
reflects abnormal repolarization or late potentials associated with delayed conduction in certain
regions of the heart. Conduction delay is a common cause for notching of the terminal QRS
complex, especially in patients with a history of myocardial infarction. Asynchronous activation
can also create voltage gradients, causing ST-segment elevation. The canine ventricular wedge
model did not represent abnormal conduction in the myocardium; it investigated the mechanism
of ER pattern in the setting of abnormal repolarization alone. The role of conduction abnormalities
in the ER pattern and arrhythmogenesis was not explored in that model.
As the results show, all ERS patients had a normal activation pattern during SR. The mean
ventricular AD (Table 3-2) was comparable with normal control. In addition to AT and activation
pattern, the morphology of EGMs was also examined in detail. Experimental and clinical studies
have shown that low-amplitude and fractionated EGMs reflect slow, non-uniform and
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discontinuous conduction through a substrate with structural heterogeneity.38 ECGI is able to
reconstruct such EGMs with high accuracy and has been used to study the EP substrate associated
with structural abnormalities including post-MI and BrS patients.5, 8, 16, 20 EGMs with abnormal
low-amplitude and fractionation were not found in ERS patients. Catheter mapping in ERS patients
did not show abnormalities during ventricular depolarization that registered with the terminal QRS
notch or slurring, confirming that the ECG J-wave was related to repolarization.69 Taken together,
these findings indicate that ventricular conduction is normal in ERS patients, and that the J-wave
on the ECG is not likely to be caused by abnormal conduction.
Figure 3-3 and Figure 3-4 demonstrate that there is significant regional abbreviation of the
AP (based on reconstructed ARIs) on the ventricular epicardium of ERS patients compared with
normal control. As shown in Figure 3-4E, in regions with abnormal EGMs, the epicardial J-wave
is followed by shortening of RT. These regions were located in close proximity to regions with
relatively longer RT. The regional differences in RT gave rise to steep RT gradients. Given the
fast and uniform conduction, the difference in ATs between two adjacent locations is too small to
account for the difference in RTs. Thus, RT and RT dispersion are primarily determined by ARI
and ARI dispersion, independent of conduction. With ARI being the surrogate for local APD,
shortened ARI suggests abbreviated AP. The formation of regions with steep gradient of
repolarization is caused by spatially heterogeneous abbreviation of the AP over short distances. In
contrast, the apex-to-base ARI dispersion (about 42 ms) and inter-ventricular ARI dispersion
(about 32 ms) result in much shallower gradients in normal subjects.13 Results from this study
are consistent with a previous case report that presented preliminary data from 2 ERS patients
mapped by ECGI.15
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Although ECG markers are currently the only noninvasive tool to identify high-risk ERS
patients, it lacks sensitivity and specificity. Each ECG electrode on the body surface records an
electric signal that reflects integrated activity over the entire heart. Therefore, spatial relationships
in the heart are lost in the body-surface ECG. It has been shown that body-surface measures do
not adequately reflect myocardial dispersion of repolarization.7 This limitation is overcome by
ECGI: it provides physiologically relevant information about myocardial repolarization by
reconstructing the actual spatial properties and dispersion on the surface of the heart.
ER and BrS are often collectively referred to as “J-wave syndromes”, because the two
conditions share similar ECG characteristics and a number of clinical features. Both are associated
with vulnerability to fatal VT/VF in young adults without apparent structural heart disease, and
have dominance in males.89 The J-wave and associated ST-segment elevation are accentuated
before the arrhythmic event, and VF is often initiated during bradycardia. Their responses to
quinidine and isoproterenol are ameliorative (normalization of the J-wave and inhibition of
VT/VF).68 Nevertheless, there are several key characteristics that distinguish ERS from BrS,
suggesting different underlying mechanisms for the ECG phenotype and arrhythmogenesis.
Moderate structural abnormalities (RV interstitial derangement), though undetectable by
noninvasive clinical imaging, have been found in endomyocardial biopsies of BrS patients, as well
as in the explanted heart of a BrS patient. 90-91 In a recent study, ECGI was performed in 25 BrS
patients.20 Altered or delayed epicardial activation in the RVOT was found in 20 patients. EGMs
with abnormally low voltage and fractionation were found in all patients. Prolonged repolarization
and steep repolarization gradients were also observed. These findings demonstrate the coexistence
of conduction and repolarization abnormalities in BrS. The abnormal EP substrate was confined
to the RVOT. In contrast, the wide-spread distribution of J-waves in ERS patients indicates that
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the EP substrate may not be localized to a specific region of the heart. The current study identifies
additional differences between ERS and BrS. Conduction delays and EGMs indicative of slow
discontinuous conduction were not found in ERS patients. The location and size of the abnormal
EP substrate varied among ERS patients. Instead of ARI prolongation in BrS patients, shortened
ARIs were observed in ERS patients during baseline SR.
There is a paucity of EP mapping data of ERS-related arrhythmias, given the small number
of ERS patients who have experienced aborted sudden cardiac death. Catheter mapping was
performed in 8 ERS patients with a history of idiopathic VF.60 In 6 patients with ER pattern only
in the inferior ECG leads, all ectopies were mapped to the inferior ventricular wall. In 2 patients
with ER pattern in both inferior and lateral leads, ectopy originated from multiple locations. In the
current study, PVCs were recorded in 2 patients. The PVC sites of origin were located in an
epicardial region with marked J-waves and short ARIs. A recent study using ECGI in an ERS
patient during VF identified VF rotors in the inferior-lateral LV wall.92 These data suggest that
the EP substrate in the inferior and lateral LV plays an important role in the development of
arrhythmias. If a triggering ectopy interacts with a susceptible substrate of steep repolarization
dispersion at the right time, direction and orientation, unidirectional block and reentrant arrhythmia
could be initiated.
Limitations:
The control data were not obtained at the time of this study; they were recorded previously
with the same ECGI methodology.
Being the first ECGI study of ERS patients, its generalizability is limited by the relatively
small number of patients. It does not differentiate between subgroups (e.g. symptoms and
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genotype) within the population. Future large-scale ECGI studies should be conducted to establish
the potential of the approach for noninvasive arrhythmic risk stratification in ER patients.
Changes in heart rate are known to affect the ER pattern on the ECG, but this protocol was
not adopted in this study. Future studies will explore how the patterns of repolarization dispersion
respond to heart rate changes.
Several drugs (including quinidine, isoproterenol, milrinone, and cilostazol) have been
shown to have ameliorative effects on the ER pattern. Future studies should characterize drug
effects on activation and repolarization patterns. The changes in activation and repolarization could
provide additional information on the EP substrate and arrhythmia mechanisms associated with
ERS.

3.6

Conclusions:
Noninvasive ECGI revealed the presence of abnormal EP substrate in ERS patients,

characterized by a regional distribution of epicardial J-waves and shortening of APD.
Heterogeneous APD shortening leads to steep repolarization gradients. This defines a substrate
susceptible to reentrant arrhythmias, not detectable by the surface ECG. Conduction abnormalities
were not present. PVC sites of origin correlated with regions of J-wave presence and steep
repolarization gradients, the abnormal EP substrate mapped during SR.
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Chapter 4:

The

Cardiac

Electrophysiologic

Substrate

Underlying the ECG Phenotype and Electrogram Abnormalities in
Brugada Syndrome Patients
4.1

Abstract
Brugada syndrome (BrS) is a highly arrhythmogenic cardiac disorder, associated with an

increased incidence of sudden death. Its arrhythmogenic substrate in the intact human heart
remains ill-defined.
Using noninvasive ECG imaging (ECGI), we studied 25 BrS patients to characterize the
electrophysiologic substrate, and 6 patients with right bundle branch block (RBBB) for
comparison. Seven normal subjects provided control data. Abnormal substrate was observed
exclusively in the right ventricular outflow tract (RVOT) with the following properties (compared
to normal controls; p<0.005): (1)ST-segment elevation (STE) and inverted T-wave of unipolar
electrograms (EGMs) (2.21±0.67 vs. 0 mV); (2)delayed RVOT activation (82±18 vs. 37±11 ms);
(3)low amplitude (0.47±0.16 vs. 3.74±1.60 mV) and fractionated EGMs, suggesting slow
discontinuous conduction; (4)prolonged recovery time (RT; 381±30 vs. 311±34 ms) and
activation-recovery intervals (ARIs; 318±32 vs. 241±27 ms), indicating delayed repolarization;
(5)steep repolarization gradients (ΔRT/Δx= 96±28 vs. 7±6 ms/cm, ΔARI/Δx= 105±24 vs. 7±5
ms/cm) at RVOT borders. With increased heart rate in 6 BrS patients, reduced STE and increased
fractionation were observed. Unlike BrS, RBBB had delayed activation in the entire RV, without
STE, fractionation, or repolarization abnormalities on EGMs.
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The results indicate that both, slow discontinuous conduction and steep dispersion of
repolarization are present in the RVOT of BrS patients. ECGI could differentiate between BrS and
RBBB.

4.2

Introduction
Brugada syndrome (BrS) is an inherited disorder, affecting predominantly males in their

40s93 and associated with an increased incidence of sudden cardiac death (SCD). It presents with
ECG expression of atypical right bundle branch block (RBBB) pattern and ST-segment elevation
(STE) in leads V1-V3.93-94 It is estimated that BrS causes approximately 20% of SCD in cardiac
patients with structurally normal hearts.93 Understanding its pathophysiological mechanisms is
essential for improving risk stratification, diagnosis and treatment to prevent SCD.
BrS is considered a primary electrical cardiac disease, since no structural anomalies are
detected by conventional imaging. Up to 30% of patients test positive for mutations in the SCN5A
gene,93 which causes a loss-of-function of the cardiac sodium channel (INa). A Brugada ECG
pattern can be provoked, in some affected patients with a normal baseline ECG pattern, by
administration of INa blockers.
There are two leading hypotheses for mechanisms underlying BrS phenotype and
arrhythmias. (1) The abnormal repolarization hypothesis (based on the canine wedge
preparation):95-97 Phase-1 notch is present in epicardial action potentials (AP) due to a high
density of transient outward current (Ito), but absent in endocardial APs (low Ito density). A reduced
INa in BrS exaggerates the phase-1 notch preferentially in right ventricular outflow tract (RVOT)
epicardium, where Ito is expressed with maximal density. The resulting voltage gradients give rise
to STE on the ECG. Further outward shift of the balance between INa and Ito can repolarize the
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membrane during phase-1 below the voltage range for L-type calcium channels (ICa-L) activation.
When ICa-L fails to activate, the AP loses its plateau (dome). Spatially heterogeneous loss of the
AP plateau in the RVOT can lead to reentry (termed “phase-2 reentry” by Antzelevitch and
colleagues). (2) The abnormal conduction hypothesis (based on whole–heart studies in BrS
patients):90,

98-99

Impaired INa in structurally deranged tissue causes slow discontinuous AP

propagation. Asynchronous activation can promote reentrant arrhythmias and create voltage
gradients, causing STE and fractionation on the ECG. Data from catheter mapping98 showed that
delayed conduction and abnormal electrograms (EGMs) with low voltage and fractionated late
potentials (reflecting slow discontinuous conduction) were exclusively localized in the anterior
aspect of the RVOT epicardium. Catheter ablation in this area normalized the Brugada ECG and
prevented ventricular tachycardia (VT). The pathophysiological mechanisms of the abnormal ECG
and arrhythmia in BrS are still a subject of debate.
While much is known at the molecular and cellular scales, understanding the cause of the
BrS ECG pattern and associated arrhythmias requires detailed characterization of the
electrophysiologic (EP) substrate in the intact hearts of BrS patients. This requires high resolution,
panoramic EP mapping of the ventricles and cannot be achieved with invasive catheter mapping.
The recent development of noninvasive mapping with Electrocardiographic Imaging (ECGI)
allowed us to obtain the first high resolution panoramic EP data from BrS patients, including up
to 1500 unipolar epicardial EGMs and epicardial maps of activation and repolarization.5-6, 10, 13, 16,
19, 100

Based on these data recorded during sinus rhythm (SR), we characterized the EP substrate in

BrS patients in an effort to provide insight into the mechanistic origin of the BrS phenotype. The
results show that both, repolarization and structurally-based conduction abnormalities coexist in
hearts of BrS patients. We also compared the BrS EP substrate to non-BrS RBBB (generally
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considered benign) to determine whether the substrate is specific to BrS, and whether ECGI can
differentiate between these two pathologies with similar ECGs.

4.3

Methods

4.3.1

Patient Population
Twenty-five BrS patients from two centers in the United States and one in France were

enrolled. The BrS diagnosis was based on the consensus criteria93 and was the basis for patient
recruitment. Beyond the consensus criteria, pregnant women and children were excluded. Patient
demographic data are provided in Table 4-1. Six RBBB patients with a prolonged QRS>120ms
were studied for comparison. All BrS and RBBB patients had no evidence of structural heart
disease on echocardiography or MRI. Data from seven normal subjects13 provided normal control.
Cumulative subject characteristics are provided in Table 4-2. Protocols were approved by the
Institutional Review Boards at the three centers; written informed consent was obtained from all
patients.
4.3.2

Noninvasive Mapping
ECGI methodology was described previously5-6, 10, 13, 16, 100 (Figure 4-1). Briefly, torso

surface ECG potentials, recorded simultaneously from 250 electrodes, were combined
mathematically with patient-specific heart-torso geometry from ECG-gated computed tomography
(CT) to construct epicardial potentials, unipolar EGMs, and maps of epicardial activation and
repolarization. Bipolar EGMs were constructed for fractionation analysis. The method was
validated extensively for reconstruction of EGMs,5-6 activation10, 13 and repolarization.6, 13
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Patient
ID

Age

Gender

SCN5A
Mutation

Previously
Aborted
SCD

Syncope

Family History
of SCD/
Brugada ECG

ICD
Implanted

ICD
Therapy

ECG Leads
with STE

BrS-1

34

M

-

+

-

-

+

+

V1, V2, V3

BrS-2

53

M

+

+

-

+

+

-

V1, V2

BrS-3

54

M

+

-

+

+

-

-

V1

BrS-4

48

M

+

-

+

+

-

-

V1, V2

BrS-5

52

M

+

-

+

+

-

-

V1, V2

BrS-6

62

F

+

-

-

+

-

-

V1

BrS-7

43

M

-

-

-

-

-

-

V1, V2

BrS-8

41

M

+

-

+

-

-

-

V1, V2, V3

BrS-9

66

M

-

-

-

-

-

-

V2

BrS-10

29

M

-

+

-

+

+

-

V1, V2, V3

BrS-11

44

M

+

-

-

+

-

-

V1, V2

BrS-12

45

M

-

-

-

-

-

-

V1, V2

BrS-13

78

M

N/A

+

-

-

-

-

V1

BrS-14

60

M

-

+

-

-

+

+

V2

BrS-15

31

M

+

-

-

-

-

-

V1, V2

BrS-16

30

M

N/A

-

-

+

-

-

V1, V2, V3

BrS-17

54

F

-

-

+

+

-

-

V1, V2

BrS-18

63

M

+

+

-

+

+

-

V2, V3

BrS-19

61

M

N/A

-

+

-

+

-

V1

BrS-20

45

M

N/A

+

-

-

+

+

V1, V2, V3

BrS-21

39

M

N/A

+

-

-

+

+

V1, V2

BrS-22

48

M

+

+

-

-

+

-

V1, V2

BrS-23

19

M

+

+

-

-

+

-

V1

BrS-24

45

M

N/A

-

+

+

-

-

V1

BrS-25

49

M

N/A

-

-

+

+

-

V1, V2

Table 4-1: BrS Patient Demographics
ICD = Implantable Cardioverter Defibrillator; SCD = Sudden Cardiac Death; STE = ST Segment
Elevation.
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Age (Year)
Male
SCN5A Mutation
Previously Aborted SCD
Syncope
Family History of SCD or
Brugada ECG
ICD Implant
ICD Therapy

BrS (n=25)
48±13
23 (92%)
11 (44%)
10 (40%)
7 (28%)

RBBB (n=6)
41±12
6 (100%)
N/A
0 (0%)
0 (0%)

Control (n=7)
28±7
4 (57%)
N/A
0 (0%)
0 (0%)

12 (48%)

0 (0%)

0 (0%)

11 (44%)
4 (16%)

0 (0%)
0 (0%)

0 (0%)
0 (0%)

Table 4-2: Cumulative Subject Characteristics
Data are presented as mean±SD or number (percentage) of patients. ICD = Implantable Cardioverter
Defibrillator; SCD = Sudden Cardiac Death.

Figure 4-1: ECGI Procedure and Parameters
Panel A: The noninvasive ECGI procedure. Body surface potential recordings (250 electrodes)
and gated, non-contrast thoracic computed tomography (CT) scan are processed mathematically
to obtain epicardial potentials, 1500 unipolar electrograms, and maps of epicardial activation and
repolarization. Panel B: The right ventricular outflow tract (RVOT) region in one patient’s heart
(shown in red) as determined from CT images. This representative image serves as an example.
Panel C: Temporal fiducial points on electrograms. AT: activation time; RT: recovery time; ARI:
activation recovery interval.
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Spatial properties of the EP substrate were determined by dividing the epicardium into 6
segments based on CT images (the RVOT is depicted in Figure 4-1B). EGMs from valvular regions
were excluded. On average, 1154 EGMs per patient were used for analysis.
EGMs were evaluated for morphology, magnitude and fractionation. EGM Brugada
morphology was defined as STE followed by T-wave inversion. EGM magnitude (EMM) was
measured peak-to-peak during the EGM QRS; for fractionated EGMs, the measurement was
confined to the fractionated segment. Fractionation was expressed as number of low-amplitude
deflections per EGM and displayed on epicardial EGM deflection maps (EDMs).16 For the
fractionation analysis, bipolar EGMs were approximated by time derivatives of unipolar EGMs.
Local activation time (AT, referenced to beginning of QRS in ECG lead II) was determined
by the maximal negative slope of the EGM during QRS inscription (Figure 4-1C). From the ATs,
epicardial activation isochrone maps were created. Slow conduction is represented by crowded
isochrones. Regional activation duration (AD) was defined as the interval between the earliest and
latest AT in a region, considering all EGMs in that region.
Local recovery time (RT) was determined from the maximal positive slope of the EGM Twave (Figure 4-1C); it reflects the sum of local activation time and local action potential duration
(APD).

For a given activation sequence, RT determines spatial voltage gradients during

repolarization, and underlies ST-T deflections. RT dispersion provides substrate for unidirectional
block and reentry. Activation-recovery interval (ARI) was defined as the difference between RT
and AT. ARI is independent of AT and a surrogate for local APD.71 Epicardial RT and ARI
gradients were computed as the difference between neighboring epicardial nodes, divided by the
distance between them.
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ECGI was conducted in 6 patients during increased heart rate (HR; 3 with exercise and 3
with isoprenaline). ECGI maps at baseline and during the faster HR were compared.
4.3.3

Simulation
The O'Hara-Rudy (ORd) model of a human ventricular myocyte101 was used in the

simulations. Fast/late INa and Ito were replaced by formulations used previously to represent the
prominent phase-1 repolarization notch characteristic of RVOT APs.102 The model was paced to
steady state at normal and slow rates (1,000 beats at 1 and 0.5 Hz, respectively) with various
combinations of reduced INa and enhanced Ito conductances (GNa and Gto). Combinations were
selected to span a virtual Brugada severity space. APD was measured at 90% repolarization
(APD90 in ms).
4.3.4

Statistical Analysis
For every subject, the mean values for EGM variables within each epicardial segment were

computed. All statistical tests were performed at the level of epicardial segments. Differences in
variables among epicardial segments were compared by one-way repeated measures ANOVA.
When the assumption of sphericity was violated, Greenhouse-Geisser correction was performed.
Using the Bonferroni method, pairwise comparisons between RVOT and other regions were
conducted (5 tests in total). Continuous variables at baseline and increased HR were compared by
paired t-test. Continuous variables between BrS and control, and between BrS and RBBB were
compared by unpaired t-test. The Satterthwaite modified t-test was used for variables with unequal
variances. All tests with P<0.05 were considered statistically significant. Statistical analysis was
performed using SPSS v19.
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RVOT

RV Free
Wall

RV Apex

LV Base

LV Free
Wall

LV Apex

Mean Peak
2.21±0.67
0.13±0.09*
0*
0*
0.08±0.04*
0*
STE (mV)
Mean EGM
0.47±0.16
2.52±0.94* 3.77±0.85* 2.99±1.17* 3.14±0.81* 5.88±1.18*
Magnitude
(Fractionated)
(mV)
Mean EGM
Fractionation
2.97±0.69
1.04±0.80*
0*
0*
0*
0*
(# of
deflections)
Table 4-3: EGM Properties for BrS Patients
Variables presented as mean±SD. *P<0.005 when comparing other segments to RVOT. EGM
= Electrogram; STE = ST-segment elevation.

4.4
4.4.1

Results
BrS Abnormal EGM Characteristics and Localization
Table 4-3 summarizes values of EGM parameters in each epicardial segment for baseline

HR. Pairwise multiple comparisons between the RVOT and other regions suggest that the
abnormal substrate is localized in the RVOT.

Figure 4-2 shows EGM characteristics and

localization for representative examples in 3 BrS patients (normal maps are provided for
reference). STE (examples in Panel A) was observed in RVOT of all 25 patients (2.21±0.67 vs. 0
mV in control, p<0.005), but rarely detected outside the RVOT. Three patients had low-magnitude
STE in the RV free wall and two in the left ventricular (LV) free wall (range from 0.2 to 0.5 mV).
ECG leads with STE for all patients are identified in Table 4-1. 59% of EGMs in RVOT had
STE>1 mV. EGMs magnitude (Panel B) was lower in the RVOT (0.47±0.16 vs. 3.74±1.60 mV in
control, p<0.005) than in other regions (>2.5mV). 46% of EGMs in the RVOT had voltage<2 mV.
Four patients had low voltage in the RV free wall and 3 in the LV base. Fractionated EGMs (Panel
C) were present in the RVOT (number of deflections =2.97±0.69 vs. 0 in control, p<0.005). 27%
of EGMs in the RVOT had more than 2 deflections. Two patients had fractionated EGMs in the
RV free wall. Panel D shows EGMs from locations marked by white dots in Panel C, representative
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of abnormal morphology of RVOT EGMs. Red arrows indicate low voltage and fractionated
EGMs.

Figure 4-2: Abnormal Epicardial Electrograms (EGMs) Characteristics and Localization
Panel A: Peak ST Segment elevation (STE) magnitude map. Insets show ECG lead V2. Panel B:
EGM magnitude map (EMM). Panel C: EGM deflection map (EDM) showing number (#) of low
amplitude deflections. BrS maps are in 3 right columns; left column shows corresponding maps
from a normal subject for reference. Panel D: Unipolar EGMs from locations marked by white
dots in Panel C. 1-Anterior RVOT, 2-Lateral RVOT, 3-RV free wall, 4-RV apex, 5-LV free wall
(EGMs from other LV sites are also normal). Red traces: time derivatives of fractionated QRS.
The derivatives approximate bipolar EGMs and emphasize fractionation. Maps are shown in
anterior view. Each BrS column shows maps/EGMs from one patient identified by BrS#. RA:
right atrium, LA: left atrium, RV: right ventricle, LV: left ventricle, RVOT: right ventricular
outflow tract, PT: pulmonary trunk. Red arrows point to low voltage and fractionated EGMs.
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Figure 4-3: Activation and Repolarization during Sinus Rhythm
Panel A: Activation times isochrone maps (AT). Lower panels: zoom on the RVOT. Panel B:
Activation-recovery interval maps (ARI). Panel C: Recovery time maps (RT). Epicardial
breakthroughs are indicated by asterisks. Isochrones are depicted in thin black lines. Black
arrows in the RVOT zoom maps of Panel A point to slow conduction indicated by crowded
isochronal lines. Red arrows in Panels B-C point to regions with steep repolarization gradients.

4.4.2

BrS Activation
Normal human epicardial activation patterns during SR were reported previously.13, 72 In

general, earliest epicardial activation occurs in anterior RV (although there are many variants of
location),13, 72 while lateral LV base is most commonly the latest region to activate. Activation
isochrone maps in Figure 4-3A show examples of how SR epicardial activation patterns were
altered by the presence of BrS EP substrate. Patient BrS#4 had earliest epicardial breakthrough
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(asterisk) over the RV free wall, from which activation propagated slowly (crowded isochrones)
across the RVOT-RV free wall border. RV free wall and LV activated first, leaving the anterior
RVOT to activate last (light blue). Patient BrS#15 had a similar activation pattern, with a broader
wavefront and faster activation of the RV free wall. Slow conduction occurred in the RVOT
(crowded isochrones in the blue region). Patient BrS#20 had earliest activation in the anterior RV.
Latest activation (dark blue) occurred at the lateral RVOT, nearly 65 ms after the anterior RV
breakthrough.
Of the 25 BrS patients imaged during SR, 20 demonstrated altered or delayed epicardial
activation at the RVOT. Table 4-4: Activation and Repolarization Parameters for BrS
PatientsTable 4-4 summarizes AT (mean ± standard deviation) in each segment. AT in RVOT
(82±18 vs. 37±11 ms in control, p<0.005) was almost as late as that of LV base (80±16 ms), and
was much delayed compared to the other 4 segments. In specific RVOT locations, AT was as late
as 150 ms. AD (the time needed for activation of a defined region) was calculated for the RVOT
(36±16 ms), the RV free wall (16±3 ms), the entire RV (40±14 ms), the entire LV (27±5 ms) and
both ventricles (51±10 ms). RVOT activation took much longer than RV free wall or LV. AD of
the RVOT accounted for about 71% of total AD in both ventricles, highlighting the slow activation
of the RVOT.

RVOT
Mean AT (ms)
Mean RT (ms)
Mean ARI (ms)

82±18
381±30
318±32

RV Free
Wall
52±12*
272±42*
229±36*

RV
LV Base
Apex
57±7*
80±16
263±30* 317±38*
221±37* 245±40*

LV Free
Wall
62±8*
279±31*
222±31*

LV Apex
58±10*
272±31*
220±27*

Table 4-4: Activation and Repolarization Parameters for BrS Patients
Variables presented as mean±SD. *P<0.005 when comparing other segments to RVOT.
Activation-Recovery Interval; AT=Activation Time; RT=Recovery Time.
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ARI=

4.4.3

BrS Repolarization
Figure 4-3 Panel B and Panel C show representative ARI and RT maps from 3 BrS patients.

Table 4-4 provides ARI and RT in each epicardial segment. ARI prolongation (318±32 vs. 241±27
ms in control, p<0.005) and RT prolongation (381±30 vs. 311±34 ms in control, p<0.005) were
observed primarily in the RVOT, but also extended into adjacent neighboring regions of the RV
free wall and the LV free wall. Steep epicardial ARI gradients and RT gradients (red arrows)
occurred mostly at the RVOT-RV free wall or RVOT-LV free wall borders. These gradients also
existed within the RVOT. Transitions of colors from blue to red across these regions reflect large
differences in ARI and RT of 70-140 ms, leading to very steep localized ARI gradients (105±24
vs. 7±5 ms/cm in control13, p<0.005) and RT gradients (96±28 vs. 7±6 ms/cm in control, p<0.005).
In patient BrS#15, the gradients between the anterior and lateral RVOT ARI map are not apparent
in the RT map. This is because the anterior RVOT activated about 40 ms later than the lateral
RVOT. This long delay masks the ARI differences between these two regions. However, in regions
that activate without conduction delay (e.g., RV free wall) RTs and their dispersion are primarily
determined by ARI and ARI dispersion, independent of conduction. The patterns in RT maps
closely follow the ARI patterns in such cases.
4.4.4

Effects of Increased HR in BrS
ECGI was performed in 6 BrS patients during increased HR (mean increase from 71 to 133

BPM) Figure 4-4 shows the effects of increased HR (from 72 to 115 BPM) in one representative
example. Although the activation sequence remained largely unchanged (Panel A), RVOT
activation was further delayed with HR increase (AD: from 32±7 ms to 38±10 ms), and RVOT
EGMs had more fractionation and lower voltage (Panels D-F). This change of RVOT EGMs was
observed in 4 out of 6 patients (no significant change in the other 2 patients). When HR increased,
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ARIs (Panel B, corrected for HR) were shorter over the entire heart, but the RVOT ARIs decreased
more than in other regions (by 50 ms compared to 25 ms in RV free wall). The regions with steep
ARI gradients persisted, but the magnitude of the ARI gradient decreased (from 117 ms/cm to 96
ms/cm). Reductions in RT and RT gradients were also observed during increased HR. STE (Panel
C) in RVOT was significantly reduced (from 2.0 mV to 0.5 mV). Similar changes in ARI, RT and
STE were observed in all 6 patients (Table 4-5).

Figure 4-4: Effects of Increased Heart Rate (HR)
Panel A: Activation isochrone maps (AT). Panel B: Activation-recovery interval maps (ARI).
Panel C: Peak ST segment elevation magnitude maps (STE). Panel D: Electrogram deflection
maps (EDM), showing number (#) of deflection on EGM. Panel E: Electrogram magnitude
maps (EMM). Panel F: EGMs from RVOT locations marked by white dots in Panel D. Each
panel shows the map at resting (75 BPM) and increased HR (115 BPM).
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Mean AT
(ms)

Mean RT
(ms)

Mean ARI
(ms)

Mean Peak
STE (mV)

Mean EGM
Fractionation

Baseline
HR
Faster
HR
Baseline
HR
Faster
HR
Baseline
HR
Faster
HR
Baseline
HR
Faster
HR
Baseline
HR
Faster
HR

RVOT

RV Free
Wall

RV
Apex

LV
Base

LV Free
Wall

LV Apex

84±14

57±16

61±8

84±11

65±10

60±7

81±19

56±15

63±7

84±10

63±8

58±8

392±26

265±38

274±34

333±42

284±39

281±38

358±30§

251±35

265±29

320±36

275±33

274±37

328±35

222±41

224±42

256±44

229±37

231±24

287±33§

203±32

210±39

239±40

218±36

220±22

2.56±0.71

0.09±0.08

0

0

0.13±0.04

0

0.84±0.26§§

0.06±0.06

0

0

0.12±0.04

0

2.73±0.53

0.87±0.54

0

0

0

0

3.65±0.60§§

1.09±0.41

0

0

0

0

Table 4-5: Effects of Increased Heart Rate (HR) in BrS Patients
Variables presented as mean±SD. §P<0.05 when compared to baseline HR; §§P<0.005 when
compared to baseline HR. ARI= Activation-Recovery Interval; AT= Activation Time; EGM=
Electrogram; RT= Recovery Time; STE= ST-segment Elevation.

4.4.5

Comparison between BrS and Non-BrS RBBB
ECGI was conducted during sinus rhythm in 6 non-BrS patients with RBBB, without

structural heart disease. Epicardial activation patterns, ARI maps and EGM morphologies were
analyzed and compared to those of the BrS patients. This comparison is of clinical importance,
because the diagnosis of BrS in the presence of an RBBB ECG could be challenging. This is
demonstrated in Figure 4-5A, where the Brugada ECG pattern for BrS#10 is masked by an RBBB
pattern. Figure 4-5 shows representative data from 4 patients (2 BrS and 2 RBBB). BrS#4 had a
spontaneous Brugada ECG pattern, while the ECG of BrS#10 showed an atypical RBBB pattern.
Table 4-6 summarizes the differences of ECGI parameters between all BrS and RBBB patients. In
RBBB patients, activation of the entire RV was delayed, with a long conduction delay of 35 ms
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across the interventricular septum (crowded isochrones; black arrow). In contrast, delayed
activation was confined to the RVOT of BrS patients. Normal RV epicardial breakthrough
(indicative of normal conduction system participation) was observed in all BrS patients, but not in
any RBBB patient. BrS patients had a much longer AD in the RVOT than RBBB patients (36±16
ms BrS vs. 14±5 ms RBBB; p<0.005), accounting for most of the AD in the entire RV (40±14 ms
BrS vs. 24±6 ms RBBB; p<0.005). Unlike BrS, RBBB T-wave inversion in the RVOT and RV
was not accompanied by ARI prolongation (RBBB=246±25 ms, BrS=326±30 ms, p<0.005), steep
ARI dispersion (RBBB=8±4 ms/cm, BrS=105±24 ms/cm, p<0.005) or steep RT gradients
(RBBB=6±3 ms/cm, BrS=96±28 ms/cm, p<0.005); ARI and RT maps were uniform. This
demonstrates that T-wave inversion per-se does not indicate the presence of repolarization
gradients. The abnormal EGM characteristics specific for BrS (STE and low amplitude
fractionation) were not observed in RBBB patients. It is of note that ECGI unmasked the presence
of BrS in BrS#10, who had an RBBB pattern on the body surface ECG but BrS substrate in the
RVOT, as revealed by ECGI.
EGM Fractionation
Activation Duration (ms)

(# of small

EGM Magnitude (mV)

deflections)
RVOT†

RV free

Entire

wall

RV†

RVOT†

RV free
wall†

RVOT†

RV free
wall

ARI

RT

Dispersion

Dispersion

(ms/cm)

(ms/cm)

RVOT†

RVOT†

BrS

36±16

16±3

40±14

2.97±0.69

1.04±0.80

0.47±0.16

2.52±0.94

105±24

96±28

RBBB

14±5

16±6

24±6

0

0

3.74±0.65

3.53±0.60

8±4

6±3

Table 4-6: A Comparison of ECGI Parameters between BrS and Non-BrS RBBB Patients
Variables presented as mean±SD. † Unpaired t-test: P<0.05. ARI= Activation-Recovery Interval;
EGM= Electrogram; RT= Recovery Time.
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Figure 4-5: Comparison between BrS and Non-BrS RBBB.
Panel A: 12-lead ECGs. Panel B: Activation isochrone maps (AT). Panel C: Activation-recovery
interval maps (ARI). Panel D: EGMs from the RVOT (top) and RV free wall (bottom). ECGs,
maps and EGMs are shown for 4 representative examples (BrS#4: spontaneous Brugada ECG
pattern. BrS#10: BrS patient with RBBB ECG pattern. RBBB#2 and RBBB#3: Non-BrS patients
with RBBB ECG patterns). Epicardial breakthroughs are indicated by asterisks. Black arrows
point to slow conduction in RVOT (BrS) or across the septum (RBBB).

4.5

Discussion
This is the first panoramic ventricular mapping study in BrS patients, made possible by

ECGI. The panoramic mapping identified the RVOT as the region of abnormal EP substrate with
the following properties: (1)Abnormal EGMs characterized by STE and inverted T-wave, reduced
amplitude and fractionation; (2)Conduction delays and regions of slow conduction; (3)Prolonged
repolarization and steep repolarization gradients; (4)Reduced STE, increased fractionation,
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decreased RVOT ARI and RT, decreased ARI and RT gradients with increased HR. These
properties are significantly different than in patients with RBBB.
4.5.1

Abnormal EGM Characteristics and Localization
The RVOT has been suggested as the origin of arrhythmic activity in BrS patients.93, 98-99,

103-104

Our observation of substrate localization exclusively to the RVOT in BrS patients provides

crucial evidence for the RVOT dominant role in clinical BrS. This is in contrast to a recent ECGI
study of the long QT syndrome, where abnormal repolarization substrate was spread over the entire
epicardium.19 ECGI revealed RVOT EGMs with coved morphology similar to the typical Brugada
ECG morphology in the body surface right precordial leads (Figure 4-2). Additionally, the EGMs
were of low amplitude and fractionated. These EGM properties, reconstructed noninvasively by
ECGI, were consistent with those obtained from invasive electroanatomical mapping.98, 103 The
ECGI panoramic mapping determined that the majority of these Brugada EGMs were confined to
the RVOT; only rarely were they detected close to the RVOT, in adjacent neighboring regions of
the RV or LV free wall. Therefore, our study adds insight to the observation from invasive
epicardial mapping and ablation, that the Brugada morphology normalized following ablation in
the anterior RVOT.98 This EGMs localization confirms that the RVOT is the origin of the
Brugada-type ECG morphology in the body surface right precordial leads.
4.5.2

Substrate for Abnormal Conduction
BrS has been considered a primary electrical disease, because structural abnormalities have

not been detectable by noninvasive clinical imaging (e.g. echocardiography or MRI). Recently,
RV interstitial derangements (fibrosis, fatty infiltration) have been found in endomyocardial
biopsies of BrS patients,90 as well as in the explanted heart of a BrS patient carrying an SCN5A
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mutation.91 Fibrosis and fatty infiltration have been associated with decreased electric coupling,
discontinuous propagation and reduced conduction velocity.27 In the normal heart, excitability and
conduction are dominated by INa. In BrS, where INa is impaired, Ito becomes a significant
determinant of excitability, opposing the depolarizing effect of INa. This is especially true in the
RVOT, where Ito is expressed with very high density. In this region, the balance between reduced
depolarizing INa and large repolarizing Ito results in a reduced excitatory current, which on the
background of a structurally abnormal substrate, can support long localized conduction delays and
discontinuous slow conduction, conditions that facilitate sustained reentrant arrhythmias.27
Experimental, theoretical, and clinical studies have shown that low-magnitude,
fractionated and wide EGMs reflect slow, non-uniform and discontinuous conduction through a
structurally heterogeneous substrate associated with separation and reduced coupling of
myocardial fibers.38 Previous studies demonstrated ECGI’s ability to reconstruct EGMs with these
properties.5, 16, 100 In this study, ECGI reconstructed low-magnitude, fractionated and wide unipolar
EGMs. The time derivatives (dV/dt) of unipolar EGMs approximate bipolar EGMs and emphasize
fractionation (Figure 4-2D, red). The reconstructed unipolar EGMs and the approximated bipolar
EGMs are consistent with those measured directly by catheters in BrS patients,98, 103 providing
evidence for slow discontinuous conduction in the RVOT. The ECGI mapping of late RVOT
activation, prolonged AD, presence of regions of slow conduction, and altered wavefront
propagation compared to normal (Figure 4-3A) provides additional evidence supporting the
conduction hypothesis. Similar observations were made with invasive mapping.98, 103 Computer
modeling of AP conduction in presence of BrS mutant INa also produced slow discontinuous
conduction, causing spatial gradients of membrane potential during the AP plateau and/or early
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repolarization phase and STE in the computed pseude-ECG waveform.105 Taken together, these
data provide evidence for the presence of abnormal conduction in the RVOT of BrS patients.
Antzelevitch and collegues used a canine RV wedge preparation, where Ito activator and
sodium and calcium channel blockers were applied to pharmacologically simulate effects of BrS,
and to explain EGM fractionation and late potentials.95-96 This preparation did not include
structural abnormalities and conduction disturbances; it investigated the mechanism of EGM
fractionation in the setting of abnormal repolarization alone. It demonstrated the ability to generate
secondary deflections on the epicardial EGMs based on differences in the AP morphology at
different epicardial locations during the AP repolarization phase. Following the phase-1 notch
(which underlies the STE), APs can differ by the presence/amplitude of a dome and by the time of
complete repolarization. The associated gradients can result in 2 late deflections on the EGM.96
Because the deflections occur during late repolarization, the shortest coupling interval to the main
EGM deflection (generated by the AP upstroke) was 200 ms.96
In the patients studied here, and in patients studied using catheters,98 EGM fractionation
shows different properties; it includes more than 2 deflections (many show 4 deflections) that are
tightly coupled to the main deflection (<50 ms) and even occur before the main deflection.
Moreover, the fractionation is amplified with increased heart rate. All of these properties point to
fragmented slow conduction as a major contributor to EGM fractionation. Of course, abnormal
repolarization can also contribute to fractionation of the EGM,96 but the augmentation with
increased heart rate identifies conduction as the major mechanism.
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4.5.3

Substrate for Abnormal Repolarization
Ito expression is non-uniform in the ventricular myocardium. Expression is highest in the

epicardium and diminishes transmurally towards the endocardium, creating a phase-1 notch in
epicardial, but not endocardial AP. A particularly large Ito density is found in the epicardial RVOT.
Reduced INa in BrS on the background of the large Ito exaggerates the phase-1 notch, and the
resulting spatial gradients of membrane voltage can give rise to STE in ECG waveforms. The deep
and wide notch delays the AP plateau and prolongs APD, potentially causing reversal of membrane
voltage gradients and T wave inversion.95, 97 In extreme cases (not recorded in this study), the
membrane is repolarized to voltages that are too low for sufficient ICa-L activation during phase-1
of the AP and cells repolarize prematurely, losing the AP plateau.95 This bi-phasic behavior (APD
prolongation followed by APD shortening in conditions of extreme severity) is supported by the
computer simulations of Figure 4-6. ECGI was validated to accurately map regions of altered
repolarization and steep repolarization gradients.6 The ECGI mapping in this study (Figure 4-3)
demonstrated delayed repolarization and prolonged epicardial APDs (based on reconstructed
ARIs) in the RVOT of BrS patients. Short ARIs, closely coupled extrasystoles, or VT were not
recorded in any patient. Interestingly, direct recordings from endocardium and epicardium
revealed longer ARIs in epicardium than in endocardium of BrS patients, suggesting prolongation
of epicardial APD; ARI shortening was not reported.106 A steep repolarization gradient existed at
the RVOT borders, which could be due to non-uniform spatial expression of the mutation.
However, even uniform spatial distribution of mutant-channel current can cause spatial ARI
dispersion. APD is determined by a delicate balance of transmembrane currents and this
dependence is non-linear. Therefore, spatially uniform mutant INa expression on the background
of non-uniform electrophysiologic profile (heterogeneous Ito) can cause large spatial variation of
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the APD. It is also possible that reduced coupling and fiber separation in the BrS substrate limit
electrical loading and help maintain the steep spatial repolarization gradients.

Figure 4-6: Computer Simulation of BrS Effects on a Human RVOT Action Potential
At pacing rate of 1 Hz and 0.5 Hz, APD90 (APD at 90% repolarization) was plotted versus I to
conductance increase (Gto from 1.0 to 2.5 fold). Colors indicate different amounts of I Na
conductance reduction (GNa from 100 to 10%). APs and their duration are shown for Gto/GNa
pairings selected to illustrate the behaviors of interest: control– A and I; AP prolongation – B,
C, E, F, J, and L; premature repolarization and AP shortening – D, G, H, and M; alternating AP
prolongation and shortening – D, E, and F, G, H. Letters A through M relate the summary data
above with each of the APs in the traces below. The simulations demonstrate bi-phasic changes
of APD (prolongation followed by shortening). Prolongation was greater when I Na was reduced.
With INa loss, there was a critical degree of Ito enhancement beyond which APs fully repolarized
prematurely at phase-1, causing loss of plateau and APD shortening. Just below this critical
degree, APs could alternate between premature repolarization and prolongation.
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4.5.4

Examining the Coexistence of Conduction and Repolarization Substrates Using
Increased HR
The rate-dependence of STE and EGM fractionation in BrS may be helpful in unmasking

the existence of abnormal repolarization and abnormal conduction, respectively, in the EP
substrate. Decreased STE at increased HR supports the repolarization hypothesis, because it
suppresses the AP phase-1 notch and associated voltage gradients. In this study, STE in the RVOT
decreased in all 6 patients with increased HR. In contrast, increased EGM fractionation with
increased HR reflects the presence of slow discontinuous conduction, consistent with the
conduction hypothesis. Increased RVOT EGM fractionation was observed in 4 patients at faster
HR. Taken together, the effects of increased HR on STE and EGM fractionation support
coexistence of these two mechanisms in the BrS substrate. Repolarization abnormality is the major
contributor to STE, while conduction abnormality is the major contributor to EGM fractionation.
From the arrhythmogenic perspective, the presence of steep repolarization gradients
(dispersion) introduces asymmetry of excitability and thus conditions for unidirectional block. 27
Slow conduction shortens the wavelength of the reentrant AP, thus allowing for shorter reentry
pathways and stabilizing reentry. Together, these two properties provide conditions for sustained
reentrant excitation. Their coexistence in the substrate of BrS patients has been suggested by other
recent studies;107-108 it is consistent with the high incidence of arrhythmic SCD. Interestingly, most
arrhythmic events occur during bradycardia. Reduced STE at increased HR reflects less steep
repolarization gradients; it reduces arrhythmogenicity because the probability for unidirectional
block is reduced.
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4.5.5

Comparison to Non-BrS RBBB
BrS and RBBB differ greatly in their arrhythmogenicity, with BrS being highly

arrhythmogenic. Therefore, a noninvasive method for distinguishing between these abnormalities
is highly desirable. Despite the similarities in the 12-lead ECG, ECGI differentiated BrS from nonBrS RBBB in several aspects: (1)BrS EGMs with STE, low voltage and fractionation were not
found in RBBB. (2)Non-delayed RV epicardial breakthrough was observed in all BrS patients,
indicating involvement of a functioning RBB. RV breakthrough was absent in all RBBB patients,
reflecting the defective conduction system. (3)In BrS, slow discontinuous conduction and delayed
activation were confined to the RVOT and RVOT-RV border. In contrast, RBBB caused late
activation of the entire RV because of a long conduction delay across the septum; there were no
regional conduction delays within the RVOT/RV. (4)ARI prolongation and steep ARI gradients
were observed in RVOT of BrS patients but not in RBBB patients. These differences could provide
the basis for an ECGI-based differential diagnosis in the clinical setting. In addition, the BrS ECG
pattern may be masked by an RBBB ECG pattern in some patients, causing difficulties in
distinguishing between BrS and RBBB. This has led to invasive procedures (e.g., RV pacing in
Chiale intervention109) that help unmask the Brugada phenotype in patients with RBBB. In this
study, we demonstrated that ECGI can image the BrS substrate in such patients, providing a
noninvasive method for the clinical diagnosis of BrS even when it is masked by an RBBB pattern
on the body surface ECG.
4.5.6

Limitations
Being the first ECGI study of BrS patients, it does not differentiate between subgroups

(genotype, symptoms, family history etc.) within the BrS population.
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ECGI data for the normal controls were previously obtained with the same ECGI
methodology; the data were not obtained at the time of this study.
This study is limited to characterizing the BrS substrate from data obtained during SR, and
relating its properties to the BrS ECG and EGM phenotype. Results demonstrate the existence of
substrate with steep dispersion of repolarization and slow conduction, conditions that facilitate
reentrant arrhythmias. However, arrhythmias were not recorded in any of the patients and the study
does not provide direct information about the mechanism of VT in BrS patients.
Typically, BrS INa is reduced to approximately 50% relative to control. Figure 4-6 shows
simulated behavior for a large range of INa reduction, paired with a range of Ito to account for its
high density in the RVOT. Deepening and broadening of the phase-1 notch, resulting in APD
prolongation, is obtained for the entire range of INa with Gto>=1.5 times control. The accentuated
notch and resulting transmembrane voltage gradients contribute to STE in BrS EGMs. However,
loss of the dome and APD shortening at 50% INa required Gto>=3.3 times control (at 1 Hz pacing).
A previously characterized BrS gain-of-function mutation in Ito, L450F, was associated with a
similarly large degree (~3-fold) of current increase.110 It should be mentioned that the simulations
were conducted in an isolated cell. In the multicellular substrate of BrS hearts, electrical loading
on the AP dome during localized conduction delays (due to structural derangement) can contribute
to premature repolarization, loss of the dome and short APD. In the 25 patients studied here, short
ARIs were never observed.

4.6

Conclusions
Noninvasive ECGI reveals that the abnormal EP substrate in BrS patients is localized in

the RVOT. Both abnormal repolarization and abnormal conduction are present in the substrate,
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leading to steep repolarization gradients and delayed activation. In addition, ECGI could
differentiate BrS from RBBB based on differences in patterns of activation and repolarization, and
EGM morphology.
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Chapter 5:
5.1

Concluding Remarks and Future Work

Concluding Remarks
The studies presented here focused on clinical application of ECGI in patients with

ischemic cardiomyopathy (ICM), early repolarization syndrome (ERS) and Brugada syndrome
(BrS). As a research tool, ECGI has provided insights into the abnormal electrophysiological (EP)
substrate that underlies these pathologies. (1) In ICM patients, the EP substrate associated with
previous myocardial infarction is characterized by the presence of low-voltage and fractionated
electrograms, late potentials and altered activation pattern during sinus rhythm. These properties
reflect structure-based abnormal conduction through the scar substrate. ECGI correlates scarrelated arrhythmia patterns with high-resolution maps of spatial characteristics of the scar EP
substrate. It also identifies key epicardial EP properties that may account for the difference in
ventricular tachycardia (VT) incidence between VT and non-VT patients. (2) In ERS patients,
regions with epicardial J-waves and steep repolarization gradients caused by regional shortening
of action potential duration are identified. Conduction abnormalities are not present. These EP
properties may account for the arrhythmogenicity in this syndrome. Activation maps during
premature ventricular contractions (PVCs) show that the PVC sites of origin are located in an
epicardial region (inferior and lateral left ventricle) with marked J-waves and steep repolarization
gradients, indicating that the EP substrate plays an important role in the development of
arrhythmias. (3) In BrS patients, the abnormal EP substrate is localized exclusively in the right
ventricular outflow tract (RVOT). The RVOT displays delayed activation, prolonged
repolarization and steep repolarization gradients. These findings reveal the existence of both,
abnormal repolarization and slow discontinuous conduction in the BrS substrate.
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ECGI also demonstrates its potential usefulness in pre-procedural guidance for catheter
ablation of scar-related ventricular tachycardia, arrhythmic risk stratification (criteria for ICD
implantation) in ICM patients, and differentiation between malignant BrS and benign right bundle
branch block.

5.2

Future Work
The present studies demonstrate that ECGI is an important research tool for understanding

the underlying EP substrate that predisposes patients to arrhythmias in various pathologies that
involve conduction abnormality, repolarization abnormality, or both. More importantly, ECGI can
be a useful clinical tool for improved diagnosis, treatment and risk stratification.
Studies in patients with ERS, BrS and long QT syndrome19 (conducted by R. Vijayakumar
et al.) constitute the first series of ECGI studies investigating the mechanisms of arrhythmogenesis
and sudden cardiac death in hereditary cardiac disorders. These studies are very important because
many of these patients are relatively young, healthy individuals without apparent structural heart
disease. The very first symptoms they experience may be ventricular fibrillation. As pilot studies,
the differences between genotypic subgroups were not investigated. Future studies should examine
the relationship between the properties of EP substrate and genotype within each disease
population.
Several drugs (e.g. quinidine, isoproterenol etc.) have been shown to have ameliorative
effects on the ER and Brugada ECG patterns. Future studies should characterize drug effects on
epicardial activation and repolarization patterns. The changes in activation and repolarization
could provide additional information on the EP substrate and arrhythmia mechanisms associated
with these disorders.
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Arrhythmic risk stratification could be one of the main directions of future ECGI
application. ICD has been prescribed for patients at the risk of ventricular arrhythmias; it is the
most effective measure for preventing sudden cardiac death. Despite this critical benefit, ICD
therapy is costly and can be associated with procedural complications and diminished quality of
life. Current clinical criteria for identifying ICD candidates rely heavily on nonspecific ECG
markers or reduction in global ventricular function (ejection fraction <35%). Only a small
percentage of patients who meet the criteria and thus undergo device implantation receive
appropriate defibrillation shocks. Development of selection criteria of higher specificity requires
knowledge of the properties of the myocardial substrate such as slow, discontinuous conduction
and repolarization gradients. As shown in the present studies, ECGI is able to image conduction
delays, elecrograms indicative of slow, discontinuous conduction and spatial dispersion of
repolarization. However, due to the research-oriented nature, the generalizability of present studies
is limited by the relatively small number of patients. Future large-scale ECGI studies should be
conducted to establish the potential of the approach for noninvasive arrhythmic risk stratification.
On the technical side, the usability and compatibility of ECGI have been enhanced over
the past few years. Examples include application of ECGI during exercise test to examine the
effects of heart rate change, improvements in the software graphical user interface for faster data
analysis and adaptation of ECGI mapping procedure to achieve compatibility with MRI, etc.
Current data analysis involving low-voltage and fractionated electrograms is still challenging and
time consuming. With sophisticated signal processing and machine learning algorithms, ECGI
should be able to handle electrogram fractionation/late potential analysis and far-filed potential
detection with faster computing and higher accuracy.
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Appendix: Case Reports
A1. Continuous ECGI Mapping of Spontaneous VT Initiation, Continuation
and Termination with Antitachycardia Pacing
A 40-year-old woman with nonischemic cardiomyopathy and a left ventricular (LV)

Figure A- 1: Continuous ECGI Mapping of Spontaneous VT Initiation, Continuation and
Termination with Antitachycardia Pacing
Panel A: Epicardial Activation Isochrone Maps. Panel B: Epicardial Potential Maps.

ejection fraction of 35% was referred for recurrent ventricular tachycardia (VT). She experienced
248 VT episodes treated by antitachycardia pacing (ATP) over 14 days. In 2005, she received an
implantable cardioverter defibrillator for an episode of syncope and nonsustained VT. She later
underwent an invasive electrophysiology study (EPS) with inducible VT and an ablation of the
AV nodal reentrant tachycardia. Since then, she experienced symptomatic VT, terminated by ATP.
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Her VT was unresponsive to sotalol and mexiletine. Two EPS in early 2010 failed to induce VT
despite intravenous isopreterenol and triple extrastimuli at two right ventricular (RV) sites;
therefore, no ablations were performed.
Upon admission, the patient underwent noninvasive Electrocardiographic Imaging
(ECGI).14, 18 Movie A-1 (available in the attached CD) shows a continuous reconstruction of
epicardial activation during initiation, continuation and termination by ATP of spontaneous VT
during ECGI procedure. The images in Figure A-1 summarize the events. Note that the VT
triggering beat differed in origin and activation sequence from the following beats of the sustained
monomorphic VT. This first VT beat (VT1) originated from the inferolateral LV base, while
subsequent VT beats (VT2…VT14) originated from the superolateral LV base with a cycle length
(CL) of 343 ms. After 14 VT beats, ATP started pacing at 85% of VT CL. The first ATP beat (P1)
was a fusion beat of the VT and right RV pacing wavefronts. The remainder ATP beats (P2...P8)
captured the ventricles and showed exclusive RV pacing pattern. The recovered atrial paced beat
following ATP was identical to the sinus beat before VT onset. ECGI identified a low-voltage
zone (scar) on posterolateral LV (Figure A-1, Panel B, dark blue).
Following ECGI, monomorphic VT with a CL of 341 ms was induced with LV
programmed stimulation in EPS. Pacing from the posterolateral LV scar yielded a QRS with a
near-perfect match to the induced VT. Ablation in this region rendered the tachycardia
noninducible. The patient has been arrhythmia-free during follow-up.
Video File (available in the attached CD):
Movie A-1: Wavefront propagation during VT initiation, continuation and termination by
ATP. The activation wavefront is shown in red. An asterisk (*) indicates the earliest epicardial
activation site. A plus sign (+) indicates the right ventricular pacing site.
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A2. Electrophysiologic Mechanism of Deteriorating Cardiac Function in a
Patient with Inappropriate CRT Indication and Frequent Ventricular Ectopy
An 84 y/o man had worsened symptoms (NYHA class III, LVEF 25%) following implant
of a biventricular (BiV) cardioverter defibrillator (Biotronik, Lumax 540) at another institution.
He also had frequent premature ventricular contractions (PVCs, 35%) that interfered with cardiac
resynchronization therapy (CRT) and triggered BiV pacing. At electrophysiology (EP) study, the
left ventricular (LV) lead was discovered to be within the anterior interventricular vein. His native
QRS (113 ms) was much narrower than during CRT; thus, BiV pacing was disabled to allow for
native conduction. The dominant clinical PVC was mapped and successfully ablated from the
coronary cusps. His symptoms improved dramatically within days of the procedure and
programming change. Prior to ablation, Electrocardiographic Imaging (ECGI)14, 18 was applied to
noninvasively map and study the mechanisms of pacing induced dyssynchrony (Figure A-2) and
ineffectiveness of PVC-triggered pacing (Figure A-3).
This patient had a narrow QRS and consequently a predictable lack of benefit from CRT
and inappropriate CRT indication.

Moreover, his LV lead was anterior, which several studies

have demonstrated not to be optimal for CRT. Inappropriate CRT in patients with synchronous
LV activation could cause pacing induced dyssynchrony, leading to deteriorating LV function.18,
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In the context of heart failure, ECGI has been used to map the EP substrate,14 to identify

potential responders/nonresponders to CRT,18 and to guide electrode placement.112 Unlike the
global body-surface QRSd, the ECGI derived cardiac electrical dyssynchrony (ED) index,
computed as the standard deviation of all activation times on the LV, quantifies the spatial
dispersion of activation over the LV (ED>28 ms is a marker of electrical dyssynchrony18).
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Figure A- 2: Activation Isochrone Maps during Native Sinus Rhythm and BiV Pacing
Panel A: QRS morphologies (12-lead ECG). Panel B: ECGI-reconstructed epicardial activation
isochrones under native sinus rhythm. Panel C: Activation isochrones during BiV Pacing. Note
that QRS in native sinus rhythm is much narrower than for BiV pacing The activation maps are
shown in right anterior oblique (top, RAO) and lateral (bottom, LAT) views. Pacing sites are
indicated by plus signs(+). QRSd and ED index are computed for each rhythm. The white arrow
highlights the U-shaped propagation pattern around a functional line of block (black arrows)
during BiV Pacing, which induced dyssynchrony. Inset: Fluoroscopy images showing the
pacing lead positions in RAO and left anterior oblique (LAO) views. RA= right atrium; LA= left
atrium; RV= right ventricle; LV= left ventricle.
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Figure A- 3: PVC Activation Isochrone Maps with and without Pacing
Panel A: QRS morphologies (12-lead ECG). Panel B: ECGI activation Isochrone maps during
PVC-triggered BiV pacing. Panel C: ECGI activation Isochrone maps during spontaneous PVC
without pacing. The activation maps are shown in posterior (top, POS) and left anterior oblique
(bottom, LAO) views. Pacing sites are indicated by plus signs (+). The earliest epicardial
activation is marked with an asterisk (*). RA= right atrium; LA= left atrium; MV= mitral valve.
PVC-triggered BiV pacing did not change the QRS morphology of the PVC (pacing occurred
during the PVC, too late to capture). There was no appreciable effect of pacing on the PVC
(Panel B, compare to Panel C). Both rhythms had identical activation patterns and similar ED
and QRSd values.

As shown in the ECGI image of Figure A-2, pacing from the early-activated LV anterior
wall during BiV created a functional line-of-block. This forced the activation front to propagate in
a U-shaped pattern around the line-of-block, causing late dyssynchronous activation of the lateral
LV base. The image in Figure A-3 shows that during PVC-triggered pacing, the PVC site of origin
was in close proximity to the anterior LV lead, but far from the RV sensing lead, which caused
delayed sensing and pacing. Thus, BiV pacing triggered by PVC failed to capture the (already
activated) ventricles and was ineffective. Because in many similar cases PVCs can impede the
effective delivery of continuous CRT, PVC treatment (catheter ablation or antiarrhythmic drugs)
to ensure high percentage of effective BiV pacing might be considered.
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